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Abstract 
 
Lignans are found as naturally occurring compounds in plants, and also as metabolites in 
mammals. Due to their biological activity, lignans have attracted the interest of scientists from 
different areas like food chemistry, synthetic chemistry, and clinical chemistry. The research 
is very active, as evident by the number of publications related to this subject that are 
published annually. 
 
The present work focuses on the chemistry of certain classes of lignan, namely lignano-9,9'-
lactones and their rearranged products. The literature review is based on the synthesis of 
lignano-9,9'-lactones and 7'-OH-lignano-9,9'-lactones. Both racemic and asymmetric 
protocols appeared as from year 2000 have been extensively reviewed. In addition, the 
literature concerning the rearrangement reaction of 7'-OH-lignano-9,9'-lactones has been 
discussed. 
 
The experimental section presents the development of a stereoselective synthesis to obtain 
7'-hydroxylignanolactones. Subsequently, the known rearrangement reactions affecting 
hydroxylignanolactones are discussed. The stereochemistry of certain lignanolactones is a 
core part of this work and the findings of this study allowed the revision of certain 
controversial data found in the literature. For the first time, the X-ray structures of 7'-OH-
lignano-9,9'-lactones were obtained. In addition, the synthesis of possible lignan metabolites 
is also presented. A summary of the available 1H NMR data for selected (7'S)- and (7'R)-OH-
lignano-9,9'-lactones and for various lignano-9,7'-lactone stereoisomers has been made 
available in the Appendix section. 
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Summary 
 
Lignans are naturally occurring compounds, found extensively in the plant kingdom, and also 
as metabolites in mammals. Scientific interest in lignans includes multidisciplinary activities 
ranging from the field of organic synthesis, to biology and biochemistry. As a result of this, 
lignan-related research is vast and heterogeneous and it would be beyond the scope of the 
thesis to exhaustively cover all of the topics. This work essentially focuses on the chemistry 
of specific lignans (selected lignanolactones). In particular the work for the development of 
an asymmetric synthesis to obtain 7'-hydroxylignanolactones is presented. In tandem, the 
rearrangement reactions affecting hydroxylignanolactones are discussed. Thanks to the 
results of this work, certain controversial data found in the literature could be corrected. 
Investigation into the stereochemistry of certain lignanolactones is also a core part of this 
work. Finally, a project for the synthesis of possible lignan metabolites will be also presented. 
To fully understand the meaning of this research, this thesis begins with an introduction to 
lignans, where the classification, the main significance, and the stereochemistry of 
lignanolactones are presented. This part will be followed by a review of the methods for the 
synthesis of lignanolactones developed as from year 2000. Both racemic and asymmetric 
syntheses will be discussed, showing how lignans continue to be in the spotlight, in the 
chemistry scene, many years after their discovery. This literature review will conclude with a 
section devoted to the rearrangement reactions of hydroxylignanolactones.  
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1 Introduction to lignans 
 
Lignans represent a large family of natural products that are widely distributed in the plant 
kingdom. This name (originally spelled lignane) was chosen by Haworth1 in 1936 to describe 
compounds possessing a skeleton structure derived from two phenylpropanoid  
(n-propylbenzene, C6C3) units connected at the central carbons of the side chains by a so-
called β-β' linkage (Fig. 1). 
 
β
2X
β'
β
 
Fig. 1. The basic structure of lignans according to Haworth’s definition.1 
 
Several naturally occurring compounds containing phenylpropanoid groups exist that are 
related to lignans, as their names also lead us to understand. Compounds in which the two 
C6C3 units are connected via a C-C bond different from β-β' are called neolignans.2 
Alternatively, when the two units are linked by an ether oxygen atom, they are identified with 
the name oxyneolignan. Structures with more than two C6C3 monomers are oligomeric 
lignans like sesquilignans/sesquineolignans (three units), and dilignans/dineolignans (four 
units). When a lignan is attached to other types of compounds (e.g. terpenes, flavonoids, 
stilbenes) it is referred to as a hybrid lignan.3 The term norlignans refers to products that 
structurally resemble lignans, but carry one less carbon atom in the aliphatic chain. Finally, 
recent studies have shown that in some species, certain lignans (like secoisolariciresinol 
glucoside) are part of a larger and complex structure, referred to as a lignan macromolecule. 
This macromolecule also includes hydroxymethyl glutaric acid, p-coumaric acid glucoside 
and ferulic acid glucoside.4 Examples of different types of C6C3 derivatives are shown in Fig. 
2. 
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Fig. 2. Examples of C6C3 unit-containing structures related to lignans. 
 
Lignans are secondary metabolites and have been found in all parts of the plants: wood, 
root, rhizome, stem, leaf, fruit and seed.5 A recently published study on the phylogenetic 
distribution of lignans in plants suggested that wide distribution seems to be linked to plant 
evolution.6 The number of naturally occurring lignans is large, due to the assorted moieties 
and functionalities present on the aliphatic7 and aromatic8 parts of the molecule. Lignan-O-
glycosides (mono- and oligosaccharides) have been isolated with D-glucose as the principal, 
but not the exclusive, carbohydrate. In this context the extraction technique plays a crucial 
role, since glycosides are cleaved under hydrolytic conditions (acid catalysis or enzymes), 
therefore only the aglycone is finally isolated. The sugar moiety is more often found in the 
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aromatic portion of the lignan, although structures where sugars are appended to the 
aliphatic part have also been identified.9,10 Most lignans are optically active compounds, with 
both enantiomers being isolated at times, depending on the producing plant.11 
 
1.1 Classification and nomenclature of lignans 
 
1.1.1 Classification 
 
The first effort to classify lignans dates back to Haworth12 who used the difference in reaction 
products between nitric acid and the ether functionality present in the molecule as a 
discrimination criterion. He divided lignans into: a) diarylbutanes, b) tetrahydronaphthalenes, 
and c) tetrahydrofurans. This initial arrangement was expanded by Hearon and MacGregor13 
who, according to the oxidation level of the aliphatic portion, classified the lignans as: a) 1,4-
diarylbutanes, b) 2,3-dibenzylbutyrolactones, c) tetrahydrofurans, d) tetrahydrofurofurans, 
and e) 4-aryltetrahydronaphthalenes. This classification was enlarged and modified in 1978 
by Weinges et al.14 who separate lignans and cyclolignans (a term which replaces the 
previously used misleading name isolignan to indicate those compounds possessing an extra 
C-C bond).15 In Weinges’ classification, still on the basis of the oxidative state of the side 
chains, lignans were described as derivatives of: a) butane, b) butanolide, c) tetrahydrofuran, 
and d) 3,7-dioxabicyclo[3.3.0]octane; while cyclolignans as derivatives of: a) 1,2,3,4-
tetrahydronaphthalene, b) hydroxymethyl-1,2,3,4-tetrahydronaphthalene carboxylic acid 
lactone, c) 3-hydroxymethylnaphthalene-2-carboxylic acid lactone, and d) 2-
hydroxymethylnaphthalene-3-carboxylic acid lactone. A third class, named isolignans 
(derivatives of benzofuran), was introduced, but this subgroup should be included among 
neolignans because it does not possess a β-β' bond. Surprisingly, this detailed classification 
omitted the large subgroup of dibenzocyclooctadienes, identified already in the early 1960s,16 
and however included later in Whiting’s review.17 Essentially, the classification commonly 
used today is based on Hearon and MacGregor’s proposal, integrated with Weinges’ and 
Whiting’s suggestions, as represented in Fig. 3.  
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a) Dibenzylbutanes b) Dibenzylbutyrolactones c) Tetrahydrofurans
O
OO
d) Tetrahydrofurofurans
OO
e) Aryltetralins f) Arylnaphthalenes g) Dibenzocyclooctadienes
O
O
OO
 
Fig. 3. Generally accepted and used classification of lignans. 
 
Concerning the aromatic part, lignans possessing variously substituted rings have been 
isolated from natural sources. Due to their biosynthesis (dimerization of coniferyl alcohol),18,19 
all plant-originated lignans are para-substituted. Aromatic substituents are oxygenated 
moieties such as hydroxy and methoxy. 
 
1.1.2 Numbering  
 
Freudenberg and Weinges15 were the first to attempt to rationalize the numbering systems, 
assigning the numbers 1-9 to the left half of the molecule (drawn following particular 
directives), according to the notation of the benzene carbon atoms (C-1 being the ipso 
carbon). For the right half of the molecule, the numbering is repeated using primed numbers 
(1'-9'). The β-β' linkage is therefore indicated as 8-8'. This system was unclear, however, as it 
depended on the way the lignan was drawn. To reduce ambiguities, Ayres and Loike20 
proposed to use unprimed numbers for that half of the molecule which contained 
functionalities with priority according to IUPAC (carbonyl has priority over alcohol) (Fig. 4, 
structure A). In case of equivalent aliphatic chains, then the aromatic part must be taken into 
account (Fig. 4, structure B). 
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Fig. 4. Lignan numbering according to Ayres and Loike.20 
 
Regrettably, different kinds of customized numbering systems (Fig. 5) have been used over 
the years, generating misunderstanding and errors (especially when applied to the naming of 
the molecules).  
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O
O
4
D
1
3
2
2'
1'
4'
3'
5'
6'
7''
 
Fig. 5. Examples of different numbering systems that can be found in the literature.21,22,23,24 
 
In the year 2000, IUPAC published the recommendations for the nomenclature of lignans 
and neolignans,25 also including the rules for a standardized numbering system. In the case 
of dibenzylbutyrolactones the numbering should be as described in Fig. 4 (structure A) 
(“lower locants required to identify the principal functional group expressed as a suffix”). 
 
1.1.3 Nomenclature 
 
A variety of trivial names and nomenclature systems have been adopted over the years 
causing mistakes and uncertainty. For example, hinokinin and cubebinolide were thought to 
be enantiomers,26 but finally they were found to be the same molecule.27 Additionally, more 
ambiguity is caused by the utilization of very similar names for different compounds (e.g. 
cubebinolide and cubebininolide),28 or by the use of the same trivial name for the glycoside 
and the aglycone. The existence of different numbering systems and classifications has also 
caused complications in the nomenclature. Again, the IUPAC recommendations25 assist by 
defining how to name a lignan. In the case of lactones the rule specifies that “lactones are 
named by changing the ending -ic acid of the corresponding acid to -lactone preceded by the 
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locant of the acid group and then the locant of the hydroxy group which forms the lactone in 
that order”. For dibenzylbutyrolactones, where the only functionality is the lactone, the IUPAC 
name is therefore lignano-9,9'-lactones. Nevertheless, since trivial names are still commonly 
used in the literature, in this work lignans will also be referred to by their trivial name, when 
this does not lead to misunderstanding.  
 
1.1.4 Presentation and description of stereochemistry 
 
Most lignans are optically active compounds, with stereogenic centers present even in the 
simplest structure (for instance at position 8 and 8'). This was known already in the early 
stage of lignan research and, in fact, the trivial names were used with the descriptors l and 
d.12 Also the (+) and (–) signs were used. These signs may be used to indicate the relative 
enantiomers, when the absolute configuration is known. Otherwise they can be misleading, 
as the sign of rotation of polarized light can change in different solvents. A more general and 
systematic description of the stereochemistry was proposed by Freudenberg and Weinges15 
who introduced the designations α and β to indicate respectively the pointing up and down of 
hydrogen atoms from the plane of the paper. Since this notation required the molecule to be 
drawn according to specific rules, the use of the unequivocal Cahn-Ingold-Prelog R/S system 
was later suggested to avoid errors.20 Surprisingly, the IUPAC recommendations recovered 
the use of the descriptors α and β, providing the directions on how to orientate a lignan 
molecule as follows: “a) unprimed numbers on the left; b) unprimed numbers 1–6 are placed 
in the lower left corner; c) primed numbers 1'–6' are placed in the lower right corner. 
Stereochemistry associated with a ring system which includes position 8 is shown by means 
of α (indicating below the plane) or β (indicating above the plane) for a bridgehead hydrogen 
(or substituent) or for a substituent attached to the ring system. If there are two substituents 
at one position, preference is given to: a) the substituent that includes a skeletal atom; b) the 
group preferred by the sequence rules. If α or β are not applicable, then R or S should be 
used.”25 
For the lignan shown in Fig. 6, drawn according to IUPAC recommendations, the complete 
name should therefore be (8α,8'β)-lignano-9,9'-lactone, which corresponds to the 8R,8'R 
configuration. In this thesis (and in the articles), the unequivocal and easily recognisable R/S 
system was preferred. 
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O
Ar Ar
O
H Hα β  
Fig. 6. The structure of a lignano-9,9'-lactone, drawn according to the IUPAC recommendations, 
showing the stereochemistry descriptors.25 
 
1.2 Ecological significance and biological activity 
 
The role of lignans in plants is not yet completely clear. At the ecological level they have, 
together with other phenylpropanoid compounds,29 a role in the plant defense.19,30 Among 
others, antifungal,31 insecticidal,32 and feeding deterrent33 properties have also been reported 
for several lignans. In addition, plant lignans exhibit a large spectrum of biological activities 
both in vitro and in vivo. A comprehensive review about the bioactivity of lignans was 
published in 200234 and integrated a few years later by an update.35 As such, anticancer,36 
antiproliferative and apoptotic effects,37 antioxidant,38 antiviral,39 and anti-inflammatory 
activities40 are all noted examples of the positive bioeffects of lignano-9,9'-lactones.41  
The use of certain lignan-rich plants or derivatives as folk medicine for the treatment of a 
range of disorders has been known for centuries. It is worth mentioning that the lignan 
podophyllotoxin 1 was the lead compound for the semisynthetic drugs Etoposide® 2, 
Teniposide® 3, and Etopophos® 4, widely used against certain types of tumors (neoplasms). 
These molecules are shown in Fig. 7. 
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Fig. 7. Podophyllotoxin 1 and derived drugs. 
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1.2.1 Mammalian lignans (enterolignans) 
 
Certain plant lignans possess a very important feature: when ingested they can be 
metabolized by the intestinal microflora and transformed into the so-called mammalian 
lignans (or enterolignans), which from a structural point of view differ from plant lignans in 
that they are not necessarily para-substituted. The mammalian lignans that were first 
recognized, and are thus most studied, are enterolactone 5 and enterodiol 6 (Fig. 8). 
Enterolactone was the first enterolignan to be detected in mammalian fluids (like plasma and 
urine) at the beginning of the 1980s.42,43,44,45 In recent years, new mammalian lignans have 
been found and identified or tentatively identified (for example 7'-OH-enterolactone 7 and 
enterofuran 8, Fig. 8).46,47,48,49 They may include other plant lignan metabolites, as well as 
metabolic derivatives of enterolactone and enterodiol.50 Investigations in this respect have 
often been delayed due to the lack of reference materials and of sensitive analytical 
methodologies. Moreover, a major problem is that enterolignans occur mainly as 
glucuronides,51 which cannot be analysed directly by most available techniques. As the 
samples need to be pretreated (acid or enzymatic hydrolysis, extraction, purification, and 
derivatisation) this may cause product loss or artefacts. While enterolactone and enterodiol 
have been the objects of several studies, the biological effects of the minor metabolites have 
not yet been studied. 
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Fig. 8. Examples of mammalian lignans (enterolignans). 
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The biological effects of mammalian lignans 5 and 6 have been under examination for 
years.52 Increasing evidence suggests they may have protective action against diverse 
health disorders such as prostate, breast, bowel, and other cancers, cardiovascular disease, 
brain function disorders, menopausal symptoms, and osteoporosis.53 The biological activity 
of enterolignans is estrogen receptor (ER) mediated, as their structures resemble that of the 
endogenous hormone 17-β-estradiol. For this reason, mammalian lignans are also called 
phytoestrogens, i.e. non steroidal naturally occurring compounds that can bind to the ER and 
produce estrogenic or/and antiestrogenic effects. They can also be regarded as endocrine 
disruptors, as they interfere with mammalian hormone function. 
For quite some time, only the plant lignans matairesinol 9 and secoisolariciresinol 10 (Fig. 9), 
or their precursor glycosides, were assumed to be metabolized into mammalian lignans, but 
this hypothesis was confuted when several other plants lignans (e.g. pinoresinol 11, and 
lariciresinol 12, Scheme 1) were found to be (at least in vitro) even more efficient mammalian 
lignan precursors.48,49,54 Good sources of plant lignans are cereals, beverages (like coffee, 
tea, and beer), fruit, berries, vegetables, and flax seed.  
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Fig. 9. First recognised plant precursors of mammalian lignans (only aglycones are shown). 
 
The metabolism of plant lignans has been extensively studied and is under continuous 
investigation. For example, the path from secoisolariciresinol 10 to enterolactone 5 has been 
well established and all the enzymes involved in this process have been identified.55,56 
The steroisomerism of the mammalian lignans, a very important consideration, and its role in 
the metabolism and in the biological activity of the enterolignans, has not been thoroughly 
studied until now. The stereochemical properties of plant lignans have been already 
anticipated in chapter 1.1.4, but what about mammalian lignans? Both enterolactone 5 and 
enterodiol 6 exist in two forms: the mirror images (8R,8'R)-(–) and the (8S,8'S)-(+) 
enantiomers. Studies show that the stereochemistry of the lignan metabolites depends on 
the configuration of the precursors.57 It appears that the metabolic reactions (e.g. hydrolysis, 
demethylation, and dehydroxylation), which are involved in the conversion of plant lignans 
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into mammalian lignans, do not affect the configuration of the C8-C8' junction. Thus, for 
example (7S,7'S,8S,8'S)-(+)-pinoresinol diglucoside 13§ is metabolized into (8R,8'R)-(–)-
enterolactone (–)-5,57 while the (8S,8'S) enantiomer (+)-5 is formed from (8S,8'S)-
secoisolariciresinol diglucoside 14 (Scheme 1).58,59 The bacteria that are responsible for 
these transformations are capable, for instance, of stereospecifically transforming only  
(–)-enterodiol into (–)-enterolactone, or (+)-enterodiol into (+)-enterolactone.60,61,62 
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Scheme 1. Examples of stereocontrolled metabolism of plant lignans into enterolignans.57,58,59 
 
The biological effects of individual mammalian lignan enantiomers have not yet been 
investigated. It is recognised that the chirality of the metabolites depends on the 
stereochemistry of their plant lignan precursors.54 Studies have shown that  
7'-hydroxymatairesinol 15, precursor of (–)-5, has anticancer effects54,63 and that the action is 
                                                
§ Note that the absolute configuration 8S,8'S of pinoresinol corresponds to the configuration 8R,8'R of 
enterolactone. 
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likely to be (–)-enterolactone-mediated. On the other hand, flax seed,64 that contains mainly 
(8S,8'S)-secoisolariciresinol diglucoside 14, precursor of (+)-5,65 is also recognised to 
possess several positive biological effects.66 Therefore if both enantiomers of enterolactone 
are biologically active, as the recent research seems to confirm, the means by which the 
enterolignans accomplish their biological activity may need to be reconsidered, and a 
mechanism other than receptor binding could eventually be implied.54 More studies on this 
topic are required. 
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2 Stereochemistry assignment 
 
As already mentioned in chapter 1.1.4, most lignans are chiral compounds and the 
determination of their absolute configuration has always attracted the interest of researchers 
since their discovery.12 In the past, the configuration assignment was done through 
interconversion, chemical transformation, and derivatization of the molecules in order to find 
a common stereochemical pattern among various lignans, and to connect them with 
stereochemically known compounds.13,67,68 The first lignan whose absolute configuration was 
determined is (–)-guaiaretic acid, a lignan with a single chiral center. Two independent 
research groups established that (–)-guaiaretic acid possesses the R configuration by 
correlating the lignan guaiaretic acid dimethylether 16 with (S)-methylbutanol 1767 or 
alternatively with (S)-3,4-dihydroxyphenylalanine 1868 (Scheme 2). Since then (R)-guaiaretic 
acid has become the model compound for assigning the configuration of chiral lignans. 
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Scheme 2. Conversion of (R)-dimethyl guaiaretic acid 16 into stereochemically known molecules.68,67 
 
In naturally occurring lignano-9,9'-lactones (with no substituents at the aliphatic chains) the 
benzyl groups almost exclusively show an 8,8'-trans relationship. Such an arrangement was 
already deduced in the late 1930s,69 and, was definitely proven in 1950 when the optically 
active (–)-matairesinol dimethyl ether (–)-19 was converted into the optically active diol (–)-20 
by LiAlH4 (Scheme 3).70 A cis relationship between the two benzylic groups of the lactone 
would have, in fact, furnished the optically inactive meso-form of diol. 
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Scheme 3. Reduction of the lactone (–)-19 to an optically active diol (–)-20 as evidence that the 
benzylic groups of (–)-19 cannot possess a cis relationship.70 
 
Correlation between 1H and 13C NMR can be used to determine the relative stereochemistry 
of lignano-9,9'-lactones, as this type of molecules present a spectrum with common pattern. 
Once the relative stereochemistry at 8 and 8' has been assigned, for example with the help 
of NOESY correlation, then the absolute configuration may be assigned, knowing the sign of 
the optical rotation, as for the 8,8'-trans lignano lactone a constancy in the sign of the optical 
rotation can be observed in most commonly used solvents. Thus, negative values have been 
consistently recorded for the 8R,8'R configuration, while the 8S,8'S isomers give positive 
values.20,57,71,72,73,74,75,76 This assumption can also be applied to the less common cis 
configuration, whereas (8R,8'S)-lignanolactones have a positive sign, while the stereoisomer 
has a negative.77,78 The absolute configuration of lignanolactones has been proven in some 
cases by X-ray diffraction.79,80,81 Furthermore, a combined conformational study of 8,8'-trans-
lignano-9,9'-lactones has been recently reported.82 
When additional stereogenic centers are present, the issues increase in complexity. The 
configuration of the 7-OH-lignano-9,9'-lactone podorhizol 21 (Scheme 4) was already 
determined in 1967.83 The acid hydrolysis of the naturally occurring podorhizol-O-glucoside 
22 furnished, among other products, podorhizol 21 and desoxypodophyllotoxin (7'S)-23 and 
isodesoxypodophyllotoxin (7'R)-23 (Scheme 4). The configurations of (7'S)-23 and (7'R)-23 
were already known as 7'S,8R,8'R and 7'R,8R,8'R** respectively.70 Anhydropodorhizol 24 
(Scheme 4), the possible intermediate in the case of α-carbonyl epimerization, was not 
found. Therefore it was deduced that 22, and consequently podorhizol 21 itself, must 
                                                
** Note that according to IUPAC recommendations for aryltetralignano-9,9'-lactones the numbering is 
different from that of lignano-9,9'-lactones. 
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possess at 8 and 8' the same trans stereochemistry as (7'S)-23 and (7'R)-23, this is to say S 
and R respectively.†† 
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Scheme 4. The transformation of podorhizol-O-glucoside 22 after acid treatment: the way how the 
configuration of podorhizol 21 was deduced.83 
 
The C-7 configuration of podorhizol was determined by IR spectroscopy as only the 7R 
epimer possesses the right geometry to form a strong intramolecular hydrogen bond 
between the 7-OH and the lactone carbonyl. In this way, naturally occurring podorhizol with 
IR peaks at 3625 cm-1, 3490 cm-1 (disappearing with strong sample dilution), and 1762 cm-1, 
was established to be the 7S,8S,8'R isomer. On the other hand, the 7R epimer (named epi-
podorhizol) with peaks at 3610 cm-1, 3500 cm-1 (which did not disappear upon sample 
dilution), and 1750 cm-1, showed the presence of an intramolecular hydrogen bond. NMR 
data also supported these conclusions. For podorhizol, the signal of H-7 at 5.28 ppm is in a 
deshielded area, while for epi-podorhizol the H-bond forces the H-7 in the shielding zone of 
                                                
†† Note that the S configuration at 8' in the 7-OH-lignano-9,9'-lactones corresponds to the R 
configuration in aryltetralignano-9,9'-lactones and in 7'-OH-lignano-9,9'-lactones. Therefore in case of 
podorhizol the 8S/8'R is the trans configuration. 
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the lactone carbonyl, giving a signal for the H-7 at 4.83 ppm. These outcomes were later 
supported by studies on the aldol condensation, a relatively easily synthetic pathway to 
obtain these types of lignans, and by further NMR investigations.84,85,86 In fact, taking into 
account that both epimers could form an intramolecular hydrogen bond, the protons H-7 and 
H-8 in the erythro compound (thus the same steric arrangement as in podorhizol) are in an 
equatorial-axial relationship (Fig. 10), with coupling constants expected to be between 2 and 
4 Hz. In the threo configuration (that of epi-podorhizol), with a trans-diaxial relationship 
between H-7 and H-8 (Fig. 10), the coupling constants are expected to be between 6 and 9 
Hz. Indeed, the H-7 signal of podorhizol has a 3J7,8 = 2.0 Hz, while the epimer a 3J7,8 = 7.5 
Hz. 
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Fig. 10. The erythro and threo aldol products and their intramolecular hydrogen bonding. 
 
The 7'-OH-lignano-9,9'-lactones have raised more problems. The 8R,8'R arrangement of  
7'-hydroxymatairesinol 15 was determined converting this lignan to the stereochemically 
known (–)-α-conidendrin (the corresponding aryltetralin lignan) but the stereochemistry at 7' 
was not determined.87 The 8R,8'R configuration of the natural compound  
(–)-parabenzlactone 25 (Fig. 11) was determined through the conversion of 25 into the 
corresponding dehydroxylated (–)-hinokinin.88 The stereochemistry at 7' was determined by 
correlating the 1H NMR signal of the secondary benzylic proton of 25 with that of podorhizol 
21 (hence H-7' vs. H-7). As shown in our recent revision (see paper I), the configuration 
assigned to (–)-parabenzlactone turned out to be wrong. Based on this erroneous 
assignment all the following studies referring to that assumption were flawed. However, for 
several years the issue was forgotten and the absolute configuration of the two 7' epimers of 
7'-hydroxymatairesinol 15 was only investigated again in the late 1990s. Despite the in-depth 
spectroscopic studies,89,90 no conclusive statement could be made, even if apparently all data 
were supporting the original (incorrect) claim derived from the comparison between 25 and 
21. The question was finally clarified by Eklund and co-workers,91 who thoroughly studied the 
natural 7'-hydroxymatairesinol 15 (mainly as mixture of the two epimers), obtained in large 
amounts from pine knots. By treating the mixture of the 7'-hydroxymatairesinol epimers with 
LiAlH4, thus reducing the lactone moiety without affecting the stereocenters, they obtained a 
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mixture of 7-hydroxysecoisolariciresinol epimers 26 (Scheme 5). The major epimer was 
obtained in a crystalline form suitable for X-ray analyses and the X-ray study revealed that it 
possesses the S configuration at the benzylic position. As a consequence, the major 7'-
hydroxymatairesinol possesses the 7'S configuration, thus opposite as previously 
assigned.89,92,93 
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Scheme 5. Reduction of 7'-hydroxymatairesinol 15 into a crystalline triol. The absolute configuration of 
isomer (7S)-26 was confirmed by X-ray analysis.91 
 
These findings were supported by the first total stereoselective synthesis of 7'-OH-lignano-
9,9'-lactones, which appeared only in 2004.94 Fischer and co-workers prepared both 7' 
isomers of 7'-hydroxymatairesinol and also of the naturally occurring 7'-hydroxyarctigenin 27, 
demonstrating that also the latter was reported in literature with the wrong configuration, the 
true one being 7'R. As we will discuss later, the work of this thesis confirms the findings of 
Eklund and Fischer, providing unambiguous evidence with the X-ray analysis of 7'-OH-
lignano-9,9'-lactones (the first X-ray for this type of lignans). In addition, the configuration of 
the other known naturally occurring 7'-OH-lignano-9,9'-lactone (–)-parabenzlactone 25 was 
also rectified as 7'S. 
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Fig. 11. Naturally occurring 7'-OH-lignano-9,9'-lactones (correct absolute configurations). 
 
As previously observed for non hydroxylated lignano-9,9'-lactones, NMR data correlations 
can be used to determine the relative configuration, also in the cases of 7 and 7'-OH 
derivatives. For example for 7'-OH-lignanolactones, once the relative stereochemistry at 8 
and 8' has been assigned by a NOESY experiment, it is then possible to compare the signal 
for the proton at 7'. It has been observed that in CDCl3, the 7'-H for the S isomer (7S relative 
to a 8R,8'R configuration) occurs at about δ 4.6 (see Annex 2, Table 7) and for the R isomer 
(7R relative to a 8R,8'R configuration) at about δ 4.4 (see Annex 2, Table 8).94 With the 
addition of other spectroscopic data (i.e. knowing the sign of the optical rotation) it is possible 
to correlate homochiral lignans and thus to determine the absolute configuration of 7'-OH-
lignano-9,9'-lactones.  
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3 Syntheses of lignano-9,9'-lactones: The state of the art as from 
the year 2000 
 
Speaking in very general terms, as this is true also for lignans, the science of synthesis is 
continuously engaged towards new methodologies for accomplishing the desired targets in 
the most efficient and effective way.  
As natural compounds, lignans have represented an interesting target for synthetic chemists. 
The variety of lignan structures, from simple to more complex arrangements, and the 
importance as biologically active compounds have engaged many scientists in developing 
new and improved strategies to obtain such molecules. 
But why to synthesize a lignan, when such molecule can be found in nature? First of all, with 
the exception of a few examples like 7'-hydroxymatairesinol 15,95 the amount of material that 
can be obtained from a plant source may be extremely small, sufficient to determine the 
structure of the molecule, but not enough for studying the biological activities, or to be 
employed in other studies. Therefore the availability of an adequate amount of material is 
crucial in many fields. Furthermore, even if the nature provides us with an amazing number 
of different structural combinations, one can always wish to have a different pattern, which 
for instance is not naturally available (or at least not yet found). So when the target is a new 
molecule, this can be synthesised with well established synthetic methods. On the other 
hand, the synthesis of lignans can be the means for the development of new synthetic tools 
and procedures, applicable later to a broader range of molecules. 
The synthetic importance of lignano-9,9'-lactones immediately stands out by observing 
Scheme 6: these structures represent a springboard for direct or indirect access to many 
other lignan types. In addition, lignano-9,9'-lactones are needed for a number of purposes, 
such as analytical and metabolic studies, biological use, quantification in various matrices, 
studies on the biosynthesis and on their role in nature.  
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Scheme 6. Lignano-9,9'-lactones give direct (normal arrows) or indirect (dashed arrows) access to 
many different lignan structures.  
 
Several synthetic approaches towards lignano-9,9'-lactones have appeared over the years 
and, as a result, a number of reviews (usually including the synthesis of various classes of 
lignans) have been published.96,97,98,99,100,101,102,103,104,105,106 The research in this field has been 
very active and many new methodologies for the synthesis of the lignano-9,9'-lactone 
framework (or possible precursors) have been developed very recently and will be discussed 
in this section. The review will cover the published literature, starting from the year 2000 (with 
few exceptions), and will also include the syntheses of β-benzyl-γ-butyrolactones,107 ideal 
precursors for lignano-9,9'-lactones, via alkylation or, when a 7-OH is desired, via aldol 
condensation (Scheme 7). The synthesis of β-benzyl-γ-butyrolactones can therefore be 
considered to be a formal synthesis of 8,8'-trans-lignano-9,9'-lactones, with the second 
benzyl moiety (at C-8) found on the opposite face of the lactone with respect to the benzyl at 
C-8' (1,2 asymmetric induction).108 For that reason, those routes with a β-benzyl-γ-
butyrolactone as an intermediate (but not specifically developed to obtain the lignan 
framework) have also been examined. 
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Scheme 7. Procedure for the synthesis of dibenzylbutyrolactones starting from β-benzyl-γ-
butyrolactones. X=H, OR. 
 
The developed protocols for the synthesis of lignano-9,9'-lactones have been collected 
according to the final product(s). Syntheses that produce racemates are discussed in chapter 
3.1; syntheses that allow the formation of optically active compounds are discussed in 
chapter 3.2. The last chapter of this section (chapter 3.3), includes the routes that allow the 
formation of an oxygenated function at C-7' in the lignano-9,9'-lactones or at the benzylic 
position in case of β-benzyl-γ-butyrolactones. In each chapter the synthetic methods are 
grouped according to the mechanism of the key step. The aromatic substituents are 
indicated as described in Annex 1. Differently oxygenated (e.g. at C-7, C-8, or C-8'), 
unsaturated (e.g. C-7=C-8), or substituted (e.g. C-9') lignano-9,9'-lactones or β-benzyl-γ-
butyrolactones have not been reviewed. 
 
3.1 Racemic syntheses 
 
3.1.1 Catalytic mechanisms 
 
A palladium-catalyzed three-component coupling reaction (Scheme 8) was the starting point 
of Balme’s approach109,110 to β-benzyl-γ-butyrolactones. The mechanism of this step is a 
sequential hetero-Michael conjugated addition-carbopalladation-reductive elimination 
process, mediated by a palladium(0) catalyst obtained in situ by the reduction of 
PdCl2(AsPPH3)2 with NaH. The obtained five membered heterocycle 28 was first 
hydrogenated to 29, and then converted into the lactone using Yb(OTf)3 as Lewis acid. The 
lactonization step involves a Lewis activation of the acetal with ring cleavage and formation 
of a stabilized malonic enolate and an oxonium species captured by methanol or water. The 
resulting alcohol can attack one of the ester groups to give the lactone. Finally, a one pot 
alkylation/decarbalkoxidation made the lignano-9,9'-lactones available as an 8,8'-trans/cis 
diastereomeric mixture (85:15).  
 
 32
O
OMeMeO2C
MeO2C
Ar
MeO2C
MeO2C
OH
O
OMeMeO2C
MeO2C
Ar
O
MeO2C
Ar
OH
H
O
Ar
O
H
Ar'
H
+
OMe
a
b
89-94%
d
68-80%
99%
87-94%
85 : 15
ArI + O
OMe
PdAr I
MeO2C
MeO2C
c
O
Ar
O
H
Ar'
H
+
28
29(±) (±)  
Scheme 8. Reagents and conditions: (a) NaH, PdCl2(AsPPH3)2 (2 mol%) THF, DMSO, 0 → 30 °C, 3 
hr; (b) H2, Pd/C, AcOEt, 10 bars, overnight; (c) Yb(OTf)3 (10 mol%), MeOH, reflux; (d) K2CO3, 
Ar'CH2Br, DMF, LiCl, H2O, 130 °C, 4 hr. Ar=Ar5, Ar16; Ar'= Ar14 (for Ar see Appendix 1).  
 
The Heck reaction was used to construct the lignan skeleton from a silanol and a disiloxane, 
which were obtained in quantitative yield from silane 30 (Scheme 9).111,112 Diester 31 was 
obtained in a good yield and with a very high regio- and stereocontrol. Intermediate 31 was 
then hydrolyzed to acid 32, which was converted into a lignanolactone via two alternative 
routes. In one route (step d, Scheme 9), 32 was esterified with phenylselenomethyl chloride 
and the product underwent a radical cyclization providing a mixture of trans/cis lactones (the 
trans being the major isomer, as expected). In the other route (step f, Scheme 9) 32 was first 
reduced to an alcohol and then converted to a seleno ester which was in turn submitted to 
the previously seen radical cyclization. The products obtained from the two routes have 
reversed aromatic substituents. The stereomeric trans- and cis-lactones could be separated 
by fractional crystallization. By mean of this procedure, the authors accomplished the 
synthesis of (±)-matairesinol 9 from the trans isomer.112 
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Scheme 9. Reagents and conditions: (a) TFA, CH2Cl2, 0 °C, 1.5 hr, then aq. NH3; (b) TBAF, TBACl, 
DMF, Ar'I, Et3N, [Pd(allyl)Cl]2 (5 mmol%) 80 °C, 40 hr; (c) KOH, EtOH, rt, 4 hr; (d) i-Pr2NEt, 
PhSeCH2Cl, NaI, Me2O, 80 °C, 18 hr; (e) Bu3SnH, AIBN, PhH, 80 °C, 4 hr; (f) LiAlH4, THF, reflux, 4 hr; 
(g) 1. Triphosgene, py, CH2Cl2, -15 → 10 °C, 2 min; 2. Et3N, PhSeH, 0 °C → rt, 30 min. Ar= Ar10, Ar16; 
Ar'=Ar1, Ar10 (for Ar see Appendix 1). 
 
Racemic dibenzylbutyrolactones were prepared by a short protocol where all the steps were 
metal catalyzed (Scheme 10).113 After a syn addition,114 the resulting E-vinylstannane 33 was 
oxidized using NMO and TPAP and two regioisomers were obtained. The bulky oxidizing 
reagent allowed a certain regioselectivity and, in fact, the desired 4-substituted lactone 34 
was obtained as the major product. The inseparable mixture of lactones was submitted to the 
Stille coupling reaction. Only 34 reacted with the benzyl bromide to furnish the monobenzyl 
butenolide 35. Hydrogenation and consecutive alkylation afforded (±)-trans-lignanolactones. 
A stereoselective version of this synthesis was also developed and is discussed later in 
chapter 3.2.1. 
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Scheme 10. Reagents and conditions: (a) Bu3SnH, Pd(PPh3)4; (b) NMO, TPAP (7.5 mol%), -78 → 
-23 °C, 62 hr; (c) ArCH2Br, Pd2(dba)3·CHCl3, AsPh3, THF, rt → reflux, 5 hr; (d) H2, Raney–Ni (T4); (e) 
LHMDS, DMPU, ArCH2Br, THF, -78 °C → rt. Ar=Ar1, Ar3, Ar9 (for Ar see Appendix 1). 
 
3.1.2 Radical mechanisms 
 
Srikrishna and Danieldoss115 based their synthetic approach on the radical cyclization of a 
bromoacetal 36, obtained in 3 steps from the benzaldehyde via the Horner-Wadsworth-
Emmons reaction, followed by a reduction and finally by a bromoacetalization reaction 
(Scheme 11). The cyclization was performed using n-Bu3SnH generated in situ. The 3:2 
mixture of ethoxy epimers was successively oxidised to give the desired lactones. 
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Scheme 11. Reagents and conditions: (a) (EtO)2P(O)CH2CO2Et, NaH, THF; (b) LiAH4, Et2O, <0 °C, 
1hr; (c) EtOCH=CH2, NBS, CH2Cl2, -70 °C, 2h; (d) n-Bu3SnCl, NaCNBH3, AIBN, t-BuOH, reflux, 90 
min; (e) Jones reagent, acetone, ultrasonication, rt, 5 min. Ar=Ar5, Ar9, Ar14, Ar18 (for Ar see Appendix 
1). 
 
Organotin reactions often give low yields, mainly due to the purification step, which can be a 
difficult task. For this reason a solid-phase synthesis was employed as a solution for this 
problem.116 Thus, a bromoacetal appended to a solid support (Merrifield resin) was used as a 
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substrate for a radical cyclization to give a product easy to isolate by simple filtration 
(Scheme 12). The last step of the synthesis, a Jones oxidation, served both to liberate the 
acetal from the solid support and to oxidize it to a lactone, without further purification. The 
yields, however, were not astonishing and the reaction required several days to be 
completed.  
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Scheme 12. Reagents and conditions: (a) NaH, THF, reflux, 20 hr; (b) NaH, Merrifield resin, THF, 
reflux, 3 days; (c) NBS, ArCH=CHCH2OH, 0 °C, 6 days; (d) Bu3SnH, AIBN, PhH, reflux, 18 hr; (e) 
Jones reagent, acetone, rt, 3 hr. Ar=Ar1 (for Ar see Appendix 1). 
 
A feasible tin-free radical protocol for the synthesis of β-benzyl-γ-butyrolactones was recently 
published (Scheme 13).117 The key intermediate is the sulfide 37, obtained in 3 steps from 5-
chloro-1-pentyne. The crucial step involves the addition of the benzenesulfanyl radical, 
generated in situ from PhSH and ACCN, to the triple bond of 37 to form a vinyl radical, 
which, in turn, generates the desired alkyl radical by homolytic substitution at the sulfur atom. 
The alkyl radical instead of being trapped by hydrogen abstraction, undergoes a 5-exo 
radical cyclization with ring enclosure onto the electron-rich C-C double bond affording the 
monosubstituted lactone. 
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Scheme 13. Reagents and conditions: (a) KOH, SHCH2CO2H, MeOH, 0 → 40-50 °C, 2 hr; (b) SOCl2, 
DMF, CH2Cl2, rt, overnight; (c) PhCH=CHCH2OH, Et3N, CH2Cl2, rt, 2 hr; (d) PhSH, ACCN, PhMe, 
reflux, 1 hr. Ar=Ar1 (for Ar see Appendix 1). 
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The oxidative coupling is a well known approach for the synthesis of lignans. A drawback of 
this method is the formation of a number of side products due to the random coupling of 
phenoxyl radical mesomers. The major side product is usually the β-5 coupling product, 
which involves the aromatic ring (C-5). To avoid this inconvenience, Zhu et al.118 blocked the 
C-5 with a t-Bu group detached at the end of the synthetic sequence (Scheme 14). The key 
coupling step, obtained by oxidation of the 5-substituted ferulic acid 38, furnished the cis 
fused dilactone 39, whereof relative cis-stereochemistry was determined by NMR (NOESY 
experiments) and also by the stereochemistry of the final product (±)-trans-matairesinol 9.  
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Scheme 14. Reagents and conditions: (a) t-BuOH, 85% H3PO4, 75 °C; (b) Br2, t-BuOH, rt; (c) 
malonate, py, piperidine, 100 °C; (d) O2, FeCl3, MeOH-H2O, rt; (e) 10% Pd/C, H2, rt; (f) DCC, THF, 
then NaBH4, THF, rt; (g) AlCl3, PhH, 50 °C. Ar=Ar21→7 (for Ar see Appendix 1). 
 
The novelty of a recently published multistep sequence is the decyanation by lithium 
naphthalenide (LN) reduction of the 8-CN lignan 40 (Scheme 15).119 The substrate for this 
reaction was obtained by submitting the cyano ester 41 to a one-pot intramolecular 
Knoevenagel condensation-hydrogenation. This reaction furnished a pair of inseparable 
diastereomers with a ratio depending on Ar. The diastereomeric mixture was alkylated to 
give only cyano dibenzylbutyrolactones with the benzylic groups in a trans configuration 
(confirmed by X-ray crystallography). Compound 41 was synthesised in 5 steps starting from 
an aldehyde. First, a Corey-Fuchs reaction, quenched with paraformaldehyde (PFA), then a 
butanethiol addition to the vinyl alcohol, followed by acidic hydrolysis and esterification with 
cyanoacetic acid. LN reduction served to remove the CN group in the last step of the 
synthesis, for on overall yield of 19-25%. The authors reported that the asymmetric version of 
the synthesis is under investigation. 
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Scheme 15. Reagent and conditions: (a) CBr4, PPh3, CH2Cl2, 0 °C, 2 hr; (b) n-BuLi, THF, -78 °C, PFA, 
rt, 3 hr; (c) BuSH, NaOH, MeCN, 75 °C, 2 hr; (d) EtOH/1N H2SO4 (4:1), 50 °C, 24 hr; (e) Me2NPOCl2, 
py, CNCH2COOH, CH2Cl2, 0 °C → rt, 24 hr; (f) L-Proline, Hantzsch ester, EtOH, rt, 24 hr; (g) 
Ar'CH2Br, K2CO3, THF, rt, 24 hr; (h) LN (3.5 eq.), THF, -45 °C, 30 min; then NH4Cl (aq.), -45 °C → rt. 
Ar=Ar1, Ar15, Ar18; Ar'=Ar1, Ar14, Ar18 (for Ar see Appendix 1). 
 
The last strategy presented in this section is illustrated in Scheme 16.120 The regioselectively 
prepared phenylselanylfuran-2(5H)-one 42 was submitted to a tandem Michael addition-
alkylation reaction, affording a mixture of diastereomers, where the major isomer is the one 
with the benzylic groups in a trans configuration, due to steric reasons. The Michael addition 
required the use of DMPU as co-solvent. The reductive elimination of the phenylselanyl 
group was performed on the diastereomeric mixture and, through a radical mechanism, 
produced mainly the more stable trans-lignanolactones. 
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Scheme 16. Reagents and conditions: (a) 1M HCl, MeCN, 0 °C, 10 min; (b) Ar2CuLi or ArMgBr/CuI, 
Et2O, -78 °C, then DMPU, Ar'CH2Br, rt, 5 hr; (c) NiCl2, NaBH4, THF, 0 °C, 5 min. Ar=Ar1, Ar5 (for Ar 
see Appendix 1). 
 
3.1.3 Miscellaneous mechanisms 
 
A Friedel-Crafts alkylation is the starting point of Taneja’s approach.121 After the ester 
formation and the reduction of ketone 43, the alcohol was formylated using the Vilsmeier 
reagent to give 44. An additional reduction furnished the primary alcohol converted into the 
final butyrolactone either via acidic hydrolysis followed by double bond reduction or, 
alternatively, by reduction followed by acidic hydrolysis. The asymmetric version of this 
reaction will be presented in section 3.2.4. 
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Scheme 17. Reagents and conditions: (a) 1. AlCl3, PhNO3, succinic anhydride, 0 → 60 °C, 3 hr; 2. 
CH2N2, Et2O; (b) H2, Pd/C (5 mmol%), EtOH, 50 psi; (c) DMF, POCl3, 0 → 40 °C, 36 hr; (d) NaBH4, 
MeOH, 0 °C; (e) 10% HCl, EtOH, 70 °C. Ar=Ar9, Ar16 (for Ar see Appendix 1). 
 
The Baeyer-Villiger (BV) oxidation represents an awesome reaction to access β-benzyl-γ-
butyrolactones. Relatively easily available 3-monosubstituted cyclobutanones 45 can be 
oxidized to lactones using peroxyacids or hydrogen peroxide (as oxygen donor) and different 
catalysts. The solvent is crucial in this kind of reaction, as it must solubilize oxygen, and 
organic substrates, but must not be oxidable. Thus chlorinated solvents are usually selected. 
Bolm and co-workers122 developed a new technique where liquid or supercritical carbon 
dioxide was used as medium. Moreover, if CO2 is used in the presence of a combination of 
molecular oxygen and an aldehyde (pivaldehyde in this specific case) as co-reductant, the 
BV reaction does not require a catalyst to proceed (Scheme 18). 
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Scheme 18. Reagent and conditions: (a) O2, compressed CO2, pivaldehyde, rt, 18 hr. Ar=Ar1 (for Ar 
see Appendix 1). 
 
3.2 Stereoselective syntheses 
 
Regardless the fact that racemic syntheses are still under continuous development (as seen 
in section 3.1), stereoselective syntheses nowadays represent the main objective in this field. 
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The need of optically active pure compounds, for example in the investigation of the chemical 
structure and behaviour of lignans, is evident, but even more obvious is the need for 
biological screening. It is well known that the biological activity of organic molecules is 
structure-dependent and, especially when looking for a possible new drug or lead compound, 
it is essential to use a single isomer. Thus, novel and (more) efficient methods to achieve 
pure enantiomers have been explored and developed in the last years. 
 
3.2.1 Catalytic mechanisms 
 
The asymmetric Baeyer-Villiger (BV) reaction is the stereoselective version of the reaction 
described in section 3.1.3 and is relatively recent, as the first chiral metal-catalyzed BV 
oxidation was reported only in 1994. The asymmetric BV reaction in lignan synthesis permits 
the access to optically active β-benzyl-γ-butyrolactones by means of desymmetrization of 
prochiral cyclobutanones. 
Bolm’s group investigated several catalytic systems with modifications affecting the metal (Al, 
Mg),123,124 the chiral chelating ligand (axially chiral binaphthol and derivatives),125,126 and also 
the oxygen donor (Scheme 19).127 The outcome (R or S) of the reaction depends on the 
chiral chelating ligand. Their best results (ee 73%) were obtained with the system BINOL-Al 
(with BINOL 46) as catalyst, and cumene hydroperoxide (CHP) as source of oxygen. For the 
first time in this type or reaction, a catalyst could be used in a substoichiometric amount (50 
mol%), and furnished modest to good ee.123 The replacement of Al with Mg (from MgI2) had a 
slightly negative effect on the enantioselectivity.124 In a later study, it was found that using the 
vaulted biaryl VANOL 47 the catalyst load could be reduced down to 20 mol%.125 The total 
conversion of the substrate was still observed, with higher yield, but unfortunately the 
enantioselectivity dropped to lower values. Using the acetylene BINOL-derivative 48 as 
ligand the catalyst load was decreased to 10 mol%, but the yield and absolute configurations 
of the products were not reported.126  
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Scheme 19. Reagent and conditions: (a) Me2AlCl + (S)-46 (1:1, 50 mol%), CHP, PhMe, -25 °C → rt, 
12 hr; or MgI2 + (R)-46 (1:1, 50 mol%), CHP, CH2Cl2, -25 °C → rt, 8 hr; or Me2AlCl + (R)-47 (1:1, 
20 mol%), CHP, PhMe, -30 °C → rt, 12 hr; or Me2AlCl + 48 (1:1, 10 mol%), CHP, PhMe, -30 °C. 
Ar=Ar1, Ar5, Ar9, Ar16 (for Ar see Appendix 1). *Conversion of the starting material determined by GC. 
 
Ding's group also explored the BV reaction to obtain chiral lactones.128 Their best results 
were obtained using a chiral phosphoric acid derived from the H8-binol-derived 49 and 
aqueous H2O2 as oxidant (Scheme 20). In this system, the solvent also played an important 
role in catalytic efficiency and asymmetric induction, and CHCl3 was proven to be the solvent 
of choice. The originality of this approach is due to the chiral Brønsted acid, used for the first 
time as an asymmetric BV oxidation catalyst. 
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Scheme 20. Reagent and conditions: (a) H2O2, 49 (10 mol%), CHCl3, -40 °C. Ar=Ar1, Ar9, Ar16 (for Ar 
see Appendix 1). 
 
A variation on the motif was recently provided by Malkov et al.129 (Scheme 21) who used 
urea-H2O2 as stoichiometric oxidant, and the complex obtained in situ by reacting 
(PhCN)2PdCl2 , ligand 50 (derived from α-pinene), and AgSbF6 as catalyst. The reaction 
furnished the R lactone with excellent yield but moderate ee. 
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Scheme 21. Reagent and conditions: (a) (PhCN)2PdCl2 (5 mol%), 50 (5 mol%), AgSbF6 (10 mol%), 
urea-H2O2, THF, -40 °C, overnight. Ar=Ar16 (for Ar see Appendix 1). 
 
A different approach was used by Buchwald.130 The key step of the sequence is the 
reduction of β-substituted butenolide 51 (Scheme 22), which was synthesized in two different 
ways: either via ring-closing metathesis of acrylate 52 using a second-generation Grubbs 
catalyst 53, or via a condensation/reduction of an aldehyde.131 51 was then 
enantioselectively reduced to β-benzyl-γ-butyrolactones using Cu(II)/(S)-p-tol-BINAP 54 as 
catalyst, and polymethylhydrosiloxane (PHMS) as reducing agent. i-PrOH was used as an 
additive to increase the yield and the speed of the reaction.  
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Scheme 22. Reagents and conditions: (a) CH2=CHCOCl, 2,6-lutidine, THF, EtOH, rt; (b) 53 (1.5 
mol%), CH2Cl2, reflux, 10 hr; (c) HCOCO2H⋅H2O, piperidine⋅HCl, dioxane-H2O, reflux, 18 hr; (d) 
NaBH4, MeOH, rt, 2 hr, then HCl; (e) CuCl2⋅2H2O (5 mol%), (S)-54 (5 mol%), t-BuONa (20 mol%), 
PMHS, pentane, rt, 2 hr; then i-PrOH, PhMe -20 °C. Ar=Ar1, Ar9 (for Ar see Appendix 1). 
 
The method developed by Yan and Spilling132 underpinned on the enantioselective addition, 
promoted by a Pd(0) catalyst, of a malonate to a chiral (1R)-phosphono allylic carbonate 
which furnished a vinyl phosphonate further transformed into a (R)-γ-lactone (Scheme 23). 
The chiral (R)-phosphonate 55 was obtained by intermolecular cross-metathesis between an 
aryl alkene and the optically active phosphonate 56, prepared in turn by a titanium alkoxide-
catalyzed phosphonylation.133 The cross-metathesis, the weak step of the route, had to be 
repeated four times on the same substrate to reach only a moderate yield. The 
enantioselective addition, instead, proceeded efficiently to give mainly the E product. The 
lactone ring was obtained by ozonolysis of 57, followed by in situ treatment with NaBH4. 
Cleavage of the t-butyl ester and decarboxylation furnished the desired (R)-lactone with 
complete chirality transfer. 
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Scheme 23. Reagents and conditions: (a) Ti(i-PrO)4, dimethyl-L-tartrate, dimethyl phosphite, Et2O,  
-15 °C, 2 hr; (b) ArCH2CH=CH2, 53 (see Scheme 22) (5 mol%), CH2Cl2, 40 °C, 12 hr; (c) Py, 
ClCO2Me, DMAP, CH2Cl2, 0 °C → rt, 24 hr; (d) NaH, Pd(PPh3)4 (3 mol%), t-BuCO2CH2CO2Me, THF, 
70 °C, 1 hr; (e) O3, MeOH, CH2Cl2, -78 °C then NaBH4, rt; (f) LiCl, DMSO, H2O, 140 °C, 17 hr. Ar=Ar3 
(for Ar see Appendix 1). 
 
Wennemers’ group recently developed a concise synthesis based on the asymmetric 
conjugated Michael-type addition of dihydrocinnamaldehyde to nitroethene (Scheme 24).134 
The reation, catalyzed by peptide 58, used in a merely 1 mol%, proceeds with high yield and 
enantioselectivity. Transformation of the aldehyde and the nitro moieties resulted in the 
formation of highly optically pure β-benzyl-γ-butyrolactone, with no homoaldol reaction of the 
aldehyde. The authors assumed that the addition reaction proceed via enamine catalysis, 
because a methylation or acetylation of the N-terminal proline residue of 58 deactivates the 
catalyst itself. The catalyst was synthesised on a solid-phase following the general protocol 
for peptide synthesis. 
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Scheme 24. Reagents and conditions: (a) 58 (1 mol%), NMM (1 mol%), CHCl3, rt, 15 hr; (b) BH3⋅THF, 
-15 °C, 1 hr; (c) NaNO2, AcOH, DMSO, rt, 12 hr, then MgSO4, 40 °C, 12 hr. Ar=Ar1 (for Ar see 
Appendix 1). 
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The same starting material as in Scheme 10 (chapter 3.1.1)113 was used for the asymmetric 
version of the synthesis. The authors’ attempt to stereoselectively reduce the benzyl 
butenolide 34 (Scheme 10) failed,135 and this problem was addressed by directly performing 
the Stille coupling on the vinylstannane 33,136 and then stereoselectively reducing the 
vinyldiol in the presence of an iridium catalyst (Scheme 25). For the Stille coupling 
optimization, several catalysts were tested, demonstrating the superiority of catalyst 59 (ee 
82%), and to a lesser extent of 60 (Scheme 25). The absolute configuration of the diol was 
established to be R by comparing the positive value of the optical rotation with the literature 
data.137 The chiral diol was then submitted to TPAP-NMO oxidation which produced two 
regioisomer lactones in a 2:1 ratio. Chromatografically isolated (R)-β-benzyl-γ-butyrolactone 
was alkylated to give a trans-(8R,8'R) lignanolactone. The authors described this lactone as 
(+), but no value was reported. Given that (8R,8'R)-dibenzylbutyrolactones generally give 
negative values, while positives values are found for (R)-β-benzyl-γ-butyrolactones, there are 
doubts as to whether the optical rotation of the final product was actually measured, or 
simply extrapolated from that of the precursor. 
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Scheme 25. Reagents and conditions: (a) ArCH2Br, Pd2(dba)3·CHCl3, AsPh3, THF, rt → reflux, 5 hr; 
(b) 59 or 60 (3 mmol%), H2, CH2Cl2, 2 hr; (c) TPAP (7.5 mol%), NMO, -78 → -23 °C, 62 hr; (d) 
LHMDS, DMPU, ArCH2Br, THF, -78 °C → rt. Ar=Ar1, Ar3, Ar5 (for Ar see Appendix 1). *(conv.) 
 
Isemori and Kobayashi138 established a method for the synthesis of β-benzyl-γ-
butyrolactones, where the pivotal step was the stereo- and regioselective alkylation of  
4-cyclopentene-1,3-diol monoacetate 61, by means of a Grignard reagent and a CuCN 
catalyst (10-30 mol%) (Scheme 26). The regioselectivity (1,4- vs. 1,2-regioisomer up to 94:6) 
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depends on the halogen atom in the Grignard reagent (Cl), the ratio between the Grignard 
reagent and the catalyst, as well as the solvent used (THF). The stereoselective reaction 
furnished only the isomer 62 described in Scheme 26.139 The synthesis continues with the 
oxidation of the alkylated pentene, the loss of a carbon atom and the formation of a lactol, 
further oxidized to β-benzyl-γ-butyrolactone. This approach showed general applicability, with 
several Ar groups tested, but in the case of Ar=Ar17, step c had to be replaced by an 
alternative route (steps h-j) due to the instability of the oxygenated benzyl groups to 
ozonolysis.  
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Scheme 26. Reagents and conditions: (a) ArMgCl, CuCN (30 mol%), THF, -18 °C, 5 hr; (b) TBSCl; (c) 
O3, Py, i-PrOH, then NaBH4; (d) TBAF; (e) KIO4, EtOH-H2O; (f) PCC, NaOAc; (g) LDA, DMPU, 
Ar'CH2Br, THF; (h) OsO4 (cat.), NMO, MeCN-THF-H2O; (i) 1. KIO4, MeCN-THF-H2O, 35 °C, 9 hr; 2. 
NaBH4. Ar=Ar1, Ar3, Ar5, Ar17; Ar'=Ar3 (for Ar see Appendix 1). 
 
3.2.2 Use of chiral auxiliaries 
 
Evans and Evans-type oxazolidinone, and imidazolidinone, auxiliaries have been recently 
largely applied for the stereocontrolled syntheses of lignano-9,9'-lactones. The utilized chiral 
auxiliaries are listed in Fig. 12. 
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Fig. 12. Chiral auxiliaries used for the synthesis of lignans. 
 
Sibi's group140 obtained both enantiomers of enterolactone 5 by modifying the order in which 
the aromatic moiety and the ester were attached to the chiral auxiliary Xc (Scheme 27). If the 
aromatic part was introduced first (step a), the final product is the (S,S)-lignanolactone. If the 
ester function was formed first (step g), then the final outcome is the (R,R) isomer. The 
syntheses are straightforward with an overall yield of 27% for the (S,S) enantiomer and 19% 
for the (R,R). The auxiliary could be recovered in more than 95% yield. 
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Scheme 27. Reagents and conditions: (a) n-BuLi, ClCO(CH2)2Ar, THF, -78 °C, 2.5 hr; (b) NaHMDS, 
ICH2CO2t-Bu, THF, -78 °C, 6 hr; (c) LiOH, H2O2, THF-H2O, 0 °C → rt, 5 hr; (d) 1. BH3⋅THF, THF, 0 °C 
→ rt, 2.5 hr; 2. p-TSA, PhH, reflux, 2 hr; (e) NaHMDS, THF, ArCH2I, -78 → -54 °C, 6-22 hr; (f) BBr3, 
CH2Cl2, 0 → -18 °C; (g) n-BuLi, ClCO(CH2)2CO2Et, THF, -78 °C, 2.5 hr; (h) NaHMDS, ArCH2I, THF,  
-78 → -54 °C, 6 hr. Xc=Xc1 (see Fig. 12); Ar=Ar3→2 (for Ar see Appendix 1). 
 
The approach presented in Scheme 28141 is the improved version of the method developed 
by Charlton in 1997.142 The novelty, here, is the replacement of the t-butyl ester with allyl 
iodide. The use of an allyl as a masked carbonyl (see later chapter 3.3.3) prevents the 
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undesired saponification during the removal of the auxyliary. Both enantiomers (8R,8'R) and 
(8S,8'S) were synthesised by simply modifying the chiral auxiliary. With this protocol, (−)-5 
was obtained in 20% overall yield. 
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Scheme 28. Reagents and conditions: (a) 1. H2, Pd/C (10%), EtOAc, rt; 2. K2CO3, BnBr, acetone-
MeCN, reflux; 3. KOH, MeOH-H2O, 70 °C; (b) 1. Et3N, t-BuCOCl, THF, -70 °C → rt, 1hr; 2. n-BuLi, 
XcH, -70 → 0 °C, 1.5 hr; (c) KHMDS, CH2=CHCH2I, THF, -72 °C, 2 hr; (d) LiBH4, MeOH, Et2O, rt; (e) 
1. OsO4, 2,6-lutidine, NaIO4, 1,4-dioxane-H2O, rt; 2. Ag2CO3, Celite, PhH, reflux, 4 hr; (f) NaHMDS, 
ArCH2I, THF, -78 °C, 2 hr. Xc= Xc2, Xc3, Xc4 (see Fig. 12); Ar=Ar3, Ar10 (for Ar see Appendix 1). 
 
Evans methodology was also exploited by Pohmakotr et al.143 (Scheme 29). The chiral 
succinic acid derivative 63 was diastereoselectively alkylated using a conventional alkylation 
protocol. After removal of the chiral auxiliary Xc, the dicarboxylic acid was converted in two 
steps to the corresponding (R)-β-benzyl-γ-butyrolactone. 
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Scheme 29. Reagents and conditions: (a) LDA, ArCH2Br, THF, -78 °C; (b) LiOH, THF-H2O, reflux, 
42 hr, then HCl; (c) Ac2O, 0 °C, 10 min; (d) NaBH4, THF, 0-5 °C, 1 hr, then HCl. Xc=Xc7 (see Fig. 12); 
Ar=Ar4, Ar5, Ar9 (for Ar see Appendix 1). 
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Bennett et al.144 have developed a short, yet not optimized, synthesis of optically active 
(8S,8'S)-lignanolactones where the significant step was the desymmetrization of succinimide 
64 by means of a chiral lithium amide base 65, capable to discriminate between a pair of 
enantiotopic protons. The enantioselective deprotonation generated an enolate which could 
be selectively alkylated (ee up to 95%) on the face anti to the bulky t-butyl substituent. The 
reaction continued with a second α-alkylation to obtain a trans-dibenzylderivative. Removal 
of the chiral auxyliary and lactonization furnished the desired lignan. 
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Scheme 30. Reagents and conditions: (a) 65, ArCH2Br, DMPU, THF, -78 °C, 3 hr; (b) LDA-LiCl, 
ArCH2Br, DMPU, THF; (c) NaBH4, i-PrOH, H2O, PhMe; (d) 2N H2SO4, 80 °C. Ar=Ar1 (racemic), Ar5 (for 
Ar see Appendix 1). 
 
3.2.3 Radical mechanisms 
 
The following three approaches use chiral auxiliaries, but are included in this section 
because their key step involves a radical mechanism. 
In the method developed by Sibi et al.145 a benzylic radical was added to a fumarate, 
desymmetrized by a chiral oxazolidinone 66 (Scheme 31). The reaction is mediated by the 
Lewis acid samarium triflate which coordinates with the imide group and makes the reaction 
highly regio- (conjugate addition β to the imide) and stereoselective (addition on the opposite 
face of the bulky group of the oxazolidinone). Bu3SnH is the radical chain carrier, while 
Et3B/O2 works as radical initiator.146 The Lewis acid activation is decisive for the radical 
addition, otherwise the reaction would be too slow and the competing hydrogenation reaction 
would be preferred. The lignan framework is completed with the second benzyl substituent 
introduced via a standard alkylation procedure. After removal of the chiral auxiliary 
(recovered in >95% yield) both enantiomer lactones could be easily achieved (see also 
Scheme 27).140  
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Scheme 31. Reagents and conditions: (a) Sm(OTf)3, CH2Cl2, THF, ArCH2Br, Bu3SnH, Et3B, O2,  
-78 °C, 3 hr; (b) NaHMDS, THF, ArCH2I, -78 → -54 °C, 26 hr; (c) LiOH, H2O2, THF-H2O, 0 °C, 3 hr; (d) 
LiBH4, Et2O, MeOH, rt, 24 h, then HCl; (e) 1. BH3⋅THF, THF, -15 °C, 18 hr; 2. p-TSA, PhH, reflux, 4 hr. 
Xc=Xc1 (see Fig. 12); Ar=Ar3, Ar9, Ar10; Ar'=Ar3, Ar10 (for Ar see Appendix 1). 
 
When symmetrically substituted lignans are the synthetic targets, Kise’s approach147 can be 
used. The method is based on the oxidative homocoupling of lithium enolates of chiral 
oxazolidinones or imidazolidinones (Scheme 32). This sequence improves an established 
methodology that was already presented a few years earlier148 and pioneered by Belletire 
and Fry.149 Several oxidants, including TiCl4, PhI(OAc)2, CuCl2, and I2, were tested and the 
best yield (81%) was obtained for both oxazolidinones and imidazolidinones with LDA-
PhI(OAc)2. Regarding their stereoselectivity, LDA-TiCl4 was observed to be the best choice 
for the oxazolidinones (trans:cis = 87:13), while the best results for imidazolidinones were 
obtained with LDA-TiCl4 and LDA-CuCl2 (trans:cis = 98:2). I2 furnished the opposite 
stereoselectivity ((R,R):(R,S) = 11:89). Hydrolysis of the dimers was obtained with LiOOH 
(for oxazolidinones) or with LiOH (for imidazolidinones). The succinic acid derivatives 67 
were finally converted to anhydrides and reduced to (8R,8'R)-lignanolactones. 
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Scheme 32. Reagents and conditions: (a) LDA, THF, TiCl4 (or PhI(OAc)2 or CuCl2 and DMPU or I2 
and DMPU), -78 °C → rt, 12-24 hr; (b) LiOH·H2O, H2O2, THF-H2O, 0 °C, 12-24 hr, then Na2SO3 4M or 
LiOH·H2O, THF-H2O, reflux, 24-48 hr; (c) 1. Ac2O, MeOH, -70 → 0 °C, 15 min; 2. NaBH4, THF, 0 °C, 1 
hr, then HCl, rt, 1 hr. Xc=Xc3, Xc8 (see Fig. 12); Ar=Ar1, Ar3, Ar5, Ar9 (for Ar see Appendix 1). 
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Baran and DeMartino150 opened a new synthetic perspective by introducing the hetero 
dimerization, this is to say the coupling between the sp3-hybridized carbon atoms of two 
different molecules (Scheme 33). This approach, based on the intermolecular oxidative 
heterocoupling of two enolates, allowed the isolation of optically pure (8R,8'R)-lignanolactone 
in 41% overall yield. With this method unsymmetrical dibenzyllignanolactones (Ar ≠ Ar') are 
easily accessible. The oxidative union between LDA-enolized oxazolidinone and 
dihydrocinnamic ester was carried out with Cu(II)-2-ethylhexanoate (Scheme 33). The poor 
diastereoselectivity of the coupling (1.6:1) did not influence the outcome of the reaction 
because the basic conditions of the last step (DBU is a strong non-nucleophilic base) 
promoted the α-epimerization to give the trans-(8R,8'R) configuration.151 The brevity of the 
sequence is also due to the simultaneous reductive cleavage of the auxiliary and the direct 
formation of the secondary alcohol. 
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Scheme 33. Reagents and conditions: (a) LDA, LiCl, PhMe, -78 → 0 → -78 °C, 30 min; (b) LDA, 
PhMe, 30 min; (c) Cu(II) 2-ethylhexanoate, -78 °C → rt, 20 min; (d) LiBH4, MeOH, THF, -78 → -10 °C, 
1.5 hr; (e) DBU, PhMe, 110 °C, 24 hr. Xc=Xc5 (see Fig. 12); Ar=Ar5, Ar'= Ar9 (for Ar see Appendix 1). 
 
The multistep sequence by Takekawa and Shishido152,153 was centred on the fragmentation 
reaction of enantiopure trisubstituted cyclopropylcarbinyl radicals (Scheme 34). Both (S)- and 
(R)-lactone enantiomers were prepared. Intermediate 68 was obtained via a Cu-catalyzed 
cyclopropanation of a diazo alkene. The lactone was reduced to a diol which was 
desymmetrized by a lipase-mediated reaction (step d, Scheme 34), responsible for the 
stereoselectivity of the whole route. The regioselectivity of the C-C bond cleavage (step f, 
Scheme 34), is controlled by the position of the radical leaving group: the bromine 69 will 
lead to the S alkene, the thiocarbonyl 70 to the R isomer. The alkenes were submitted to 
further chemical modifications to give enantiopure (ee >99%) β-benzyl-γ-butyrolactones. The 
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chirality of the cyclopropane was entirely maintained in the radical fragmentation reaction 
(step f).  
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Scheme 34. Reagents and conditions: (a) p-TsN3, aq. NaOH, Bu4NBr, CH2Cl2, rt; (b) CuSO4, 
Cu(acac)2, PhH, reflux; (c) LiAlH4, THF, rt; (d) Lipase AK, vinyl acetate, PhH, rt; (e) CBr4, Ph3P, 
CH2Cl2, rt; (f) Bu3SnH, AIBN, PhH, reflux; (g) KOH, aq. EtOH, rt; (h) TBDMSCl, imidazole, DMAP, 
DMF, rt; (i) 9-BBN, THF, 0 °C, then NaOH, H2O2, rt; (j) 1. Dess-Martin periodinane, CH2Cl2, 0 °C → rt; 
2. NaClO2, NH2SO3H, t-BuOH, H2O, rt; 3. p-TSA, CH2Cl2, rt; (k) K2CO3, aq. MeOH, rt; (l) S=C(imid)2, 
PhMe, 50 °C; (m) 1. Dess-Martin periodinane, CH2Cl2, 0 °C → rt; 2. TBAF, THF, rt; (n) 1. PCC, 
CH2Cl2, rt; 2. florisil, Et2O, rt, 30 min. Ar=Ar5 (for Ar see Appendix 1). 
 
Ryu’s group154 implemented an atom transfer carbonylation (ATC) reaction for the formation 
of butyrolactones (Scheme 35). The novelty of this ATC reaction is the use of Pd(PPh3)4 as 
catalyst during the photoirradiation. This addition permits to increase the yield and 
remarkably reduce the reaction time, very lengthy with primary alkyl iodides. The authors 
suggested Pd(0) to operate as radical initiator by reacting with RI at the early stage, and 
forming a radical R• and Pd(I)I. R• and CO generate an acyl radical which forms an 
acylpalladium by coupling with Pd(I)I and eventually gives the lactone. The chirality of the 
target (R)-β-benzyl-γ-butyrolactone is attributable to the enantiomerically pure alcohol iodide 
71, which was prepared in three steps following a published procedure.155 
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Scheme 35. Reagents and conditions: (a) 1. MsCl, CH2Cl2, Et3N, 0 °C; 2. NaI, acetone, 50 °C; 3. 
NaOMe, MeOH, rt, 1.5 hr; (b) hν (Xenon, Pyrex), Pd(PPh3)4 (5 mol%), 4-DMPA, Et3N, CO, PhH, 
45 atm, 16 hr. Ar=Ar5 (for Ar see Appendix 1). 
 
3.2.4 Enzymatic transformations 
 
The use of chemoenzymatic methods in the stereoselective synthesis (or semi-synthesis) of 
lignans is relatively new (1990s). A model of this application is represented by the Baeyer-
Villiger oxidation (Scheme 36), where biocatalysts have been largely used and are under 
continuous development. The enzymes which are capable of transforming a prochiral 
cyclobutanone into an optically active γ-butyrolactone are flavin-dependant monooxygenases 
(BVMOs). The most common enzymes are cyclohexanone monooxygenases (CHMOs), 
cyclopentanone monooxygenases (CPMOs) and hydroxyacetophenone monooxygenases 
(HAPMOs) and structural genes of these enzymes have been isolated from several 
microorganisms (bacteria, fungi). The BVMOs insert one oxygen atom from molecular 
oxygen into the substrate, while the second one is reduced to H2O by a donor. Because 
these enzymes are NADH or NADPH dependent, either an auxiliary enzyme that 
regenerates the cofactor (coenzyme regenerating enzyme) and an electron donor substrate 
are used together with the purified BVMOs, or a whole-cell system is employed for the 
reaction catalysis. Mihovilovic’s group studied several BVMOs and the outcomes are 
summarized in Table 1.156,157,158,159 For example, enantiomerically enriched  
(R)-butyrolactones were obtained using a HAPMO originating from Pseudomonas 
fluorescens ACB and expressed by E. coli TOP10 (Table 1, entry 1). The enantioselectivity 
of this enzyme may depend, according to the authors, on the distance between the bulky 
groups and the reactive carbonyl center. In fact a good enantioselectivity was observed with 
larger substituents and a spacer between the prochiral center and the phenyl group resulted 
in loss of chirality.156 Interesting feasibility studies have been conducted on the application of 
bio-engineering for the synthesis of a self-sufficient BVMO (self-sufficient because it does not 
require an additional catalyst for the coenzyme recycling).159 Two enzymes, the BVMO itself 
and a coenzyme capable of regenerating the cofactor (phosphite dehydrogenase–PTDH), 
were attached through a short linker peptide and expressed by E.coli TOP10. The electron 
donor substrate is a cheap phosphite that is converted into a phosphate. As entries 11 and 
12 in Table 1 show, the results are promising because if compared to the same BVMOs, but 
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without the appended coenzyme (entries 2 and 7 in Table 1), the reaction proceeds with 
100% conversion yield. In general, the BVMO technique gives good enantioselectivity with 
ee values up to 98-99% in several cases. Another advantage of the microbial BV compared 
to the metal catalyst version, is the "green chemistry" aspect of the procedure. However 
there are also several drawbacks, like high costs and laborious enzyme purifications steps, 
to mention only a few of them. 
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Scheme 36. Biocatalysed Baeyer-Villiger oxidation. For the details, see Table 1. 
 
Table 1. Baeyer-Villiger monooxygenases (BVMOs) in the desymmetrization of prochiral 
cyclobutanones (for Ar see Appendix 1). 
Entry BVMOs Ar1 Ar5 Ar3 Ar16 Ar14 Ref.
1 HAPMO Pseudomonas fluorescens ACB(a, b) 
Yield % 26 63 42   156 
ee % 44 (R) 66 (R) 56 (R)
2 CHMOAcinetobacter(a, b) 
Yield % 32 35 50 55 90 157 
ee % 88 (S) 97 (S) 99 (S) 97 (S) 90 (S) 
3 CHMOArthrobacter(a, b) 
Yield % 56 35 43 89 72 157 
ee % 93 (S) 98 (S) 93 (S) 97 (S) 94 (S) 
4 CHMOBrachymonas(a, b) 
Yield % 38 60 45 64 58 157 
ee % 84 (S) 90 (S) 93 (S) 90 (S) 98 (S) 
5 CHMOBrevibacterium 1(a, b) 
Yield % 30 61 74 73 72 157 
ee % 93 (S) 75 (R) 35 (S) 26 (S) 79 (R) 
6 CHMOBrevibacterium 2(a, b) 
Yield % 27 53 50 64  157 
ee % 59 (S) 37 (S) 45 (S) 24 (R) 
7 CPMOComamonas(a, b) 
Yield % 37 56 70 56  157 
ee % 31 (S) 40 (S) 45 (S) 24 (R) 
8 CHMORhodococcus 1(a, b) 
Yield % 33 45 60 53 46 157 
ee % 87 (S) 98 (S) 98 (S) 80 (S) 95 (S) 
9 CHMORhodococcus 2(a, b) 
Yield % 31 52 72 56 55 157 
ee % 87 (S) 98 (S) 98 (S) 95 (S) 92 (S) 
10 CHMOXanthobacter sp. ZL5(a, b) 
Yield % >90c >90c >90c   158 
ee % 88 (S) 99 (S) 88 (S)  
11 PTDH-CHMOAcinetobactera 
Yield % 100c 100c    159 
ee % 72 (S) 96 (S) 
12 PTDH-CPMOComamonasa 
Yield % 100c 100c    159 
ee % 28 (S) 41 (S) 
(a) Whole-cell system; (b) expressed by E.Coli; (c) conversion. 
 
 
 
 
 
 54
Enzymes have been successfully used for the desymmetrisation of racemic mixtures of 
alcohols, further converted into lignans. In the approach developed by Raviña et al.160 
racemic hydroxyl ester 72 was desymmetrised via lipase-catalysed esterification (Scheme 
37). Numerous lipases were tested and the best results were obtained using lipase from 
Pseudomonas cepacia (PS), which acetylated only the (R) alcohol. However, because of the 
unsatisfactory ee, the (R)-acetate was submitted to enantioselective lipase-catalyzed acetate 
hydrolysis and the optically pure alcohol was obtained. This was converted to the 
corresponding lactone under acidic conditions. The (S) isomer alcohol, that was not 
acetylated but obtained as such in 94% ee, was transformed directly into the (S)-lactone by 
acid treatment.  
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Scheme 37. Reagents and condition: (a) 1. KOH, MeOH, rt, 8 hr; 2. BrPr, DMF, 40 hr; (b) Lipase PS, 
vinyl acetate, rt, 24 hr; (c) Lipase PS, t-BuOH-phosphate buffer (1:6), rt, 18 hr; (d) p-TSA, PhH, reflux, 
3 hr. Ar=Ar1 (for Ar see Appendix 1). 
 
The work conducted by Achiwa et al.161 on desymmetrisation is shown in Scheme 38. 
Several lipases for the enantioselective esterification of dibenzylbutanediols were 
investigated. When a racemic diol was subjected to a lipase-mediated biotransformation, it 
furnished a separable mixture of diacetate 73, monoacetate 74 and diol 75 (Scheme 38). 
Diacetate 73 and monoacetate 74 were obtained either as (R,R) or (S,S) enantiomers, 
depending on the enzyme, in very modest ee. Diol 75, obtained in high optically purity (ee up 
to 99% with lipase AH), but disappointingly with a very poor yield (lower than 20%), was then 
oxidized with Fétizon’s reagent to the (S,S)-lignanolactone. The racemic starting material 
was prepared following established procedures (Stobbe condensation). 
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Scheme 38. Reagents and condition: (a) Lipase, vinyl acetate, rt, up to 96 hr; (b) Fétizon’s reagent 
(AgNO3, Na2CO3, Celite), PhMe, reflux, 3 hr. Ar=Ar5 (for Ar see Appendix 1). 
 
Similarly, Felluga et al.162 used a selective ester hydrolysis for the desymmetrization of nitro 
ester 76 (Scheme 39). Thus, racemic 76 was treated with α-chymotrypsin and the (R)-acid 
(ee 94%, but low yield) was then transformed into lactone.  
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Scheme 39. Reagents and condition: (a) MeNO2, DBU, rt, overnight; (b) α-chymotrypsin, phosphate 
buffer pH 7.4, H2O, rt, 15 hr; (c) TMSCl, EtOH; (d) H2, Ra-Ni, 1 atm, Boc2O, EtOH, 12 hr; (e) 2M HCl, 
rt, 30 min; (f) 1M aq. NaNO2, H2O, 0 °C → rt, overnight. Ar=Ar1 (for Ar see Appendix 1). 
 
 
 56
The asymmetric version163 of the synthesis presented in section 3.1.3 (Scheme 17)121 was 
also developed (Scheme 40). Baker’s yeast was employed to simultaneously reduce the 
double bond (stereoselectively), and the aldehyde of 42. A treatment with diluted acid 
completed the sequence and the (R)-lactone was obtained in 94% ee. 
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Scheme 40. Reagents and condition: (a) Baker’s yeast, D-glucose, H2O, 30 °C, 50 hr; (b) 10% HCl, 
70 °C, 20 min. Ar=Ar9, Ar16 (for Ar see Appendix 1). 
 
3.2.5 Miscellaneous mechanisms 
 
The long linear protocol developed by Ghosh164 (Scheme 41) commenced from the protected 
D-mannitol which was converted, through some manipulations (tandem periodate 
cleavage/Wittig-Horner reaction), into unsaturated alcohol 77 (E:Z = 4:1, not separated). The 
mixture as such was submitted to the Johnson-Claisen rearrangement165 which afforded both 
diastereomers 78 and 79 in a 1:1 ratio. The products were separated by flash 
chromatography. Compound 78, subsequent to alkylation, furnished 80 (diastereomerically 
pure after flash chromatography) which in turn, after a reduction, a series of oxidations, and a 
final decarboxylation, was converted to (S)-β-benzyl-γ-butyrolactone. Ester 79, which 
theoretically could lead to the (R)-isomer, was left at the stage of triol. 
 57
R=CO2Et
R=CH2OH, 77
R=CH=CH2
R=CO2H
R=H
O
Ar
H
H
RAr
H
H
O
O
R=CO2Et, 80
R=CH2OH
H
O
O
CO2Et
O
O
b
62%
H
O
O
CO2Et
+
c
e
95%
75%
h
84%
68%
70% 
de 83%
84%
CH2OHAr
H
H
OH
CH2OH
f
87%
O
O
O
O
OH
OH a
d
g
j
67%
OH
O
Ar
R
H
H
1 : 1
O
S
79
O
O
Ar
H
R
78
51%
i
O
O
OH
R
(78)
 
Scheme 41. Reagents and conditions: (a) NaIO4, MeCN-H2O, K2CO3, PO(OEt)2CH2CO2Et, 0 °C → rt, 
16 hr; (b) LiAlH4, Et2O, -60 °C, 2 hr; (c) MeC(OEt)3, EtCO2H, 140 °C, 6 hr; (d) LDA, THF, HMPA, 
ArCH2Br, -78 °C, 4 hr; (e) LiAlH4, Et2O, rt, 4 hr; (f) AcOH, H2O, rt, 18 hr; (g) NaIO4, MeCN-H2O, rt, 1.5 
hr; (h) Jones reagent, acetone, 0 °C; (i) NaIO4, RuCl3⋅H2O, MeCN-CCl4-H2O, 3 hr, then Jones reagent, 
acetone; (j) PhMe, reflux, 16 h. Ar=Ar3 (for Ar see Appendix 1). 
 
The classical Stobbe condensation was revised in a stereoselective fashion by Xia et al.166 
(Scheme 42). The key point of the protocol is the resolution of the dicarboxylic acid 81 with  
(–)-quinine, possible because the quinine salt of the (R)-isomer is the first to crystallise.  
(R)-81 was converted, after esterification and a double reduction, to a mixture of trans and 
cis diols. The diols were chromatographically separated and each product was oxidized to 
the respective lactone, thus (8R,8'R)- and (±)-cis-lignanolactones were obtained. The (S)-81 
isomer could be recovered from the mother liquor.  
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Scheme 42. Reagent and conditions: (a) (CH2CO2Et)2, NaOEt, EtOH, reflux, 4 hr; (b) LDA, Ar'CH2Br,  
-78 °C, 2 hr; (c) 20% aq. NaOH, reflux, 3 hr; (d) 1. (-)-Quinine, EtOH, reflux 1 hr; 2. 2N HCl, 1 hr ; (e) 
EtOH:PhH:H2SO4 (100:50:1), reflux, 36 hr, (f) 1. H2, Pd/C (10%), EtOAc, 12 hr; 2. LiAlH4, THF, 10 hr; 
then separation by chromatography; (g) Ag2CO3/celite, PhH, reflux. Ar=Ar5 (for Ar see Appendix 1). 
 
3.3 Syntheses of 7'-OH- or 7'-OR-lignano-9,9'-lactones 
 
Compared to the large number of protocols developed for the synthesis of non-oxygenated 
lignano-9,9'-lactones, discussed in the previous chapters and also appearing in the earlier 
literature, the procedures for the synthesis of 7'-OH- or 7'-OR-lignano-9,9'-lactone‡‡ have 
been until the recent years, surprisingly, very limited. To our knowledge, the first total 
racemic synthesis of a 7'-OH lignanolactone was performed in 1976,167 while the first total 
asymmetric synthesis appeared only in 2004.94 In this section, the syntheses have again 
been classified according to the key step mechanism, but the stereoselectivity of the 
reaction, this time, was not taken as discriminator. 
 
3.3.1 Catalytic mechanisms 
 
A recent approach168,169 involves a high diastereo- and enantioselective cross-aldol reaction 
which allowed the synthesis of (7'R)-7'-hydroxyenterolactone (7'R)-7 in few steps (Scheme 
                                                
‡‡ OR = O-C, O-Si, etc. 
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43). The simultaneous formation of the new C-C bond and the desired hydroxyl group is 
catalysed by L-proline, which resulted to be the best catalyst, among the several tested. It is 
interesting that the alkylation was performed directly on the unprotected alcohol 82, as all 
attempts of protecting the alcohol failed, thus explaining the modest yield of the reaction. The 
only disappointing aspect to the work is that the authors reported an extra proton in the 1H 
NMR characterisation of the final product, which hopefully was only due to an oversight.§§ 
The synthesis of (8R,8'R)-enterolactone (−)-5 was also achieved, by reduction of the alcohol 
82 followed by alkylation.  
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Scheme 43. Reagents and conditions: (a) 1. L-Proline (20 mol%), DMF, 4 °C, 24 hr; 2. NaBH4, 35-
40 °C, 10 hr; (b) LiHMDS, THF, ArCH2Br, -78 → -54 °C, 20 hr; (c) BBr3, CH2Cl2, -18 °C, 10hr, (d). 10% 
Pd/C (20 mol%), ClCH2CH2Cl, 50-60 °C, 20 hr. Ar=Ar3→2 (for Ar see Appendix 1). 
 
In the strategy recently presented by Hodgson (Scheme 44),170 a methylene lactone carrying 
a secondary alcohol 83 was obtained through a Barbier-type reaction with good 
diastereoselectivity. The following allylation, mediated by catalyst 84 ([RhCl(cod)]2), furnished 
(7'S*,8R*,8'R*)-(±)-7'-hydroxymatairesinol (±)-15. The protocol has a limited number of steps 
and does not require the use of protecting groups. 
 
                                                
§§ The authors claimed that the 1H NMR of (7'R)-7'-hydroxyenterolactone (7'R)-7 did not match with 
the previously reported data.93 This is not true if the extra signal is not accounted for.  
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Scheme 44. Reagents and conditions: (a) Me3PhN+Br3-, 1,4-dioxane, rt, 15 h; (b) LiBr/Li2CO3, DMF, 
60 °C, 10 h; (c) ArCHO, Zn, sat. aq. NH4Cl (trace), DMF, rt, 15h; (d) 84 (3 mol%), 85, 1,4-dioxane, 
H2O, 100 °C, microwave, 1h. Ar=Ar7 (for Ar see Appendix 1). 
 
The protocol recently presented by Coelho et al.171, is the improved version of a previously 
described synthesis.172,173 The starting step (Scheme 45) is a Baylis-Hillman (or Morita-
Baylis-Hillman) reaction with DABCO used as catalyst. Compared to the earlier procedure, 
the reaction time was slightly reduced and the yield increased by using an ionic liquid  
(1-butyl-3-methylimidazolium hexafluorophosphate, [bmim]PF6) and ultrasound. The addition 
product 86 was used as Michael acceptor for the nucleophilic cyanide anion. When the 
Michael addition was performed directly on the alcohol (step b, Scheme 45), the result was a 
mixture of diastereomers with a poor stereoselectivity (syn:anti = 1:1.5). The problem was 
overcome by oxidizing directly the mixture and reducing diastereoselectively the obtained 
lactone. The resulted anti cyanide 87 (diastereomeric ratio 10:1), purified by flash 
chromatography, was transformed in the final (±)-anti butyrolactone. When the Michael 
addition was performed on 88, the outcome was a 4:1 mixture in favour of the syn isomer 89. 
The mixture of diastereomers could not be entirely separated and the final product was the 
enantiomerically enriched (±)-syn alcohol, obtained in a similar way as the corresponding anti 
isomer.  
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Scheme 45. Reagents and conditions: (a) CH2=CHCO2Me, DABCO (10 mol%), [bmim]PF6, MeOH, 
ultrasound, rt, 80 hr; (b) NaCN, NH4Cl, DMF-H2O, rt, 12 hr; (c) Jones reagent, acetone, 0 °C ; (d) 
NaBH4, MeOH, 0 °C → rt, 90 min; (e) TBDMSCl, imidazol, DMF, rt, 18 hr; (f) DIBAL, CH2Cl2, -78 °C, 3 
hr; (g) NMO, TPAP, CH2Cl2, rt, 1 hr; (h) TBAF, MeOH, 0 °C 2 hr. Ar=Ar5 (for Ar see Appendix 1). 
 
3.3.2 Radical mechanisms 
 
The key step in the synthesis developed by Quayle174 is an atom transfer radical cyclization 
reaction (Kharasch-type reaction, Scheme 46). Compound 90, obtained via two different 
methods, was treated with a copper catalyst (formed in situ) to afford a 2:3 mixture of lactone 
epimers. The authors proved that this ratio was due to a post-cyclization equilibration. The 
stereochemistry of the main threo product was confirmed by X-ray analysis. The 
diastereomeric mixture afforded only the single threo benzyl alcohol (d.r. > 95:5) upon 
solvolysis. The stereoselectivity is probably due to the formation of a planar benzylic cation, 
created by the scission of the C-Cl bond, which is captured by the benzyl alcohol 
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approaching from the less hindered face of the plane. A final dechlorination gave the desired 
lactone. 
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Scheme 46. Reagents and conditions: (a) 1. Ph3P=CHCO2Et, THF, 20 °C, 2. DIBAL, THF, -78 °C, 3. 
ClCOCCl3, Et3N, Et2O, 0 °C, 3 hr; (b) CH2=CHMgBr, THF, -78 °C → rt; (c) ClCOCCl3, Et3N, Et2O, 0 °C, 
1 hr; (d) CuCl, dHbipy (5 mol%), ClCH2CH2Cl, reflux, 3.5 hr; (e) BnOH, CH2Cl2, 50 °C; (f) Bu3SnH, 
AIBN (20 mol%), PhH, 80 °C. Ar=Ar5 (for Ar see Appendix 1). 
 
Fischer and co-workers94 have the merit of having pioneered the total stereoselective 
synthesis of several enantiopure 7'-hydroxylignano-9,9'-lactones (Scheme 47). The first part 
of their strategy, where the chirality of the molecule is created effectively, is based on the 
Evans’ oxazolidinone protocol (Xc=Xc4, Fig. 12) with the formation of a syn-aldol adduct 91. 
This methodology, as will be highlighted in the next paragraphs, has been utilized by other 
research groups and the novelty of Sherburn’s sequence can be found in the steps that 
follow. After the removal of the chiral auxiliary, the synthesis proceeded with the formation of 
a thionocarbonate 92, which in turn underwent a radical domino reaction that in the end 
furnished the (7'S)-7'-TBDMSO-dibenzylbutyrolactones in acceptable yield and high 
diastereoselectivity. The proposed reaction mechanism involves the addition of the radical 
species (MR3)• to the sulfur, followed by a sequence of two 5-exo cyclizations to create two 
new C-C bonds, and two eliminations steps. After the removal of TBDMS protecting groups 
(step f), (7'S,8R,8'R)-7'-hydroxymatairesinol (7'S)-15, and (7'S,8R,8'R)-7'-hydroxyarctigenin 
(7'S)-27 were obtained. By means of this synthesis, the stereochemistry of naturally 
occurring 7'-hydroxyartigenin was proved to be incorrectly assigned (should have been 7'R 
instead of 7'S). The synthetic strategy was smartly concluded with the inversion of the 
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stereochemistry of the hydroxyl group at C-7' via a modified Mitsunobu reaction (step g, 
Scheme 47). In the case of (7'S)-15 (Ar=Ar'=Ar7), the phenols had to be re-protected as the 
TBDMS derivatives prior to the Mitsunobu reaction. This was not necessary in case of (7'S)-
27 (Ar=Ar9, Ar'=Ar7).  
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Scheme 47. Reagents and conditions: (a) 1. n-Bu2BOTf, Et3N, ArCHO, CH2Cl2, -78 → 0 °C, 1 hr; 2. 
H2O2, pH 7.2 buffer, Et2O, rt, 48 hr; (b) TBDMSOTf, 2,6-lutidine, CH2Cl2, rt, 30 min; (c) NaBH4,  
THF-H2O, rt, 16 hr; (d) Py, Ar'OCSCl, CH2Cl2, 25 °C, 2 hr; (e) TMSSiH, AIBN, PhH, 80 °C;  
(f) TBAF, AcOH, THF, rt, 96 hr; (g) 1. PPh3, p-NO2C6H4CO2H, DEAD, PhH, rt, 48 hr; 2. K2CO3, 
KHCO3, MeOH-H2O, rt, 1 hr; (h)TBDMSCl, imidazole, DMF, 25 °C ,2 hr. Xc=Xc4 (see Fig. 12); Ar= Ar9, 
Ar11→7; Ar'= Ar11→7 (for Ar see Appendix 1). 
 
3.3.3 Use of chiral auxiliaries 
 
The first part of the strategy discussed above (chapter 3.3.2) was also adopted by Yamauchi 
et al.175,176 However, as the antipode of the Evans’ oxazolidinone R-imide was used as 
starting material (Xc=Xc2, Fig. 12), S-butyrolactones were obtained as final product (Scheme 
48). 
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Scheme 48. Reagents and conditions: (a) n-Bu2BOTf, Et3N, CH2Cl2, ArCHO, -78 → 0 °C, 1 hr; (b) 
TIPSOTf, 2,6-lutidine, CH2Cl2, rt, 1 hr; (c) LiBH4, MeOH, THF, rt, 16 hr; (d) OsO4, NMO, aq. acetone,  
t-BuOH, rt, 48 hr; (e) NaIO4, MeOH, rt, 16 hr; (f) PCC, CH2Cl2, rt, 16 hr. Xc=Xc2 (see Fig. 12); Ar=Ar5 
(for Ar see Appendix 1).  
 
In a similar way, Xie et al.177,178 (Scheme 49) employed the Evans' oxazolidinone strategy 
using a homochiral auxiliary as that in Scheme 48, but obtaining an opposite outcome. The 
reason for this is that MgCl2 in the presence of TMSCl and Et3N promotes the formation the 
non-Evans anti-aldol adduct. Thus (7'R,8R,8'R)-hydroxymatairesinol 15 was the final product 
of the procedure. 
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Scheme 49. Reagents and conditions: (a) MgCl2, TMSCl, Et3N, EtOAc, 0.5 hr; (b) TBDMSCl, 
imidazole, DMF; (c) LiBH4, Et2O-H2O; (d) OsO4, NaIO4, 2,6-lutidine, dioxane/H2O; (e) PCC, molecular 
sieves, CH2Cl2, 2 hr; (f) LHMDS, HMPA, ArCH2Br, THF, -78 °C, 3 hr; (g) TBAF, THF; (h) H2, Pd/C, 
EtOH, 4 hr. Xc=Xc6 (see Fig. 12); Ar=Ar10→7 (for Ar see Appendix 1). 
 
The routes developed by Sherburn,94 Yamauchi175 and Xie177 represent an interesting way to 
control the output of a synthesis, simply by altering the catalyst, or the chiral auxiliary, 
showing the versatility of Evans’ chemistry in the lignan synthesis. 
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The general methodology explored by Enders and co-workers already in 1996,179 was 
recently revived to fashion 7'-hydroxylignanolactones.180,181 The protocol is centred on chiral 
α-aminonitriles 93, obtained via the Strecker reaction, which act as Michael donors, to afford 
diastereoselectively the (S) adducts 94. Alkylation and hydrolysis of the chiral auxiliary 
furnished the 8,8'-trans-7'-oxolignanolactone in high optical purity. The ketone was then 
reduced to give an epimeric mixture of alcohol, further oxidized to (8S,8'S)-lignanolactones.  
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Scheme 50. Reagents and conditions: (a) 93, MeOH (or H2O), AcOH (or HCl), KCN, pH = 4–5; (b) 1. 
LDA, THF, -78 °C, 90 min; 2. butenolide, -78 °C; (c) t-BuLi, THF, -78 °C, 90 min; 2. Ar'CH2Br, -90 → 
0° C; (d). AgNO3, H2O, THF, 25 °C; (e) NaBH4, MeOH/CH2Cl2; (f) H2, Pd/C, HClO4, MeOH, 4 atm., rt. 
Ar=Ar1, Ar5; Ar'=Ar1, Ar5, Ar9, Ar14 (for Ar see Appendix 1). 
 
Yamauchi182 developed a different strategy based on the aldol addition of the enantiopure 
(S)-trityloxypentanolide 96, prepared from L-glutamic acid, to an aromatic aldehyde (Scheme 
51). In this case, the stereoselectivity of the new C-C bond is controlled by the ether moiety. 
The erythro and threo aldol reaction products (ratio 1:1) were chromatographically separated 
and individually used to obtain chiral β-benzyl-γ-butyrolactones with an opposite benzylic 
configuration: the S from the erythro isomer and the R from the threo. The synthesis was 
straightforward and according to the authors the most challenging step was the selective 
removal of the trityl ether without affecting the methoxymethyl ether. The orthogonal 
deprotection was accomplished using formic acid and prior protection of the primary alcohol 
as pivaloyl ester. In successive publications, the authors presented variations on some 
reagents and on the protecting group management steps (MOM replaced by TIPS to avoid 
the t-BuCO protection), but the overall yield diminished from 28% to 15-18% as a result.38,183 
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Scheme 51. Reagents and conditions: (a) LDA, ArCHO, THF, -75 °C, 1 hr, then separation by 
chromatography; (b) MOMCl, i-Pr2NEt, CH2Cl2, rt, 16 hr; (c) 1. LiAlH4, THF, 0 °C, 30 min; 2. t-BuCOCl, 
py, rt, 17 hr; (d) HCO2H, Et2O, -5 °C, 1 hr; (e) 1N aq. NaOH, EtOH, rt, 20 hr; (f) NaIO4, aq. t-BuOH (or 
MeOH), rt, 2 hr; (g) Ag2CO3-Celite, PhMe, reflux, 1 hr. Ar=Ar5, Ar10, Ar20 (for Ar see Appendix 1). 
 
A similar strategy was adopted to synthesise a cis-8,8'-lignanolactone (Scheme 52).184,185 
Compared to the procedure described in Scheme 51, the stereoselectivity of the aldol 
reaction was improved by using, as starting material, (3R,4S)-R-hydroxy-S-trityloxy-4-
pentanolide 97, prepared from L-arabinose. The hydroxyl group of the chiral auxiliary is the 
crucial moiety that directs the stereoselectivity of the new C-C bond and also increases the 
yield of threo alcohol at the expense of the erythro product (9:1 ratio). The epimers were 
chromatographically separated and the major isomer 98 was used to carry on the synthesis 
similarly as described in Scheme 51. A key point of the protocol is the formation of the 
hemiacetal 99 as a single isomer, with epimerization at C-3. After conversion of 99 into a 
lactone, removal of the hydroxyl group via a thionoformate, and alkylation, the last step 
involved a rearrangement of the trisubstituted 7',8'-cis-8,8'-trans-lignano-9,7'-lactone, which 
will be discussed in more detail in chapter 4. Thus the cis-8,8'-parabenzlactone was 
synthesised in a 5% overall yield from pentanolide 97. 
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Scheme 52. Reagents and conditions: (a) LDA, ArCHO, THF, -75 °C, 1 hr, then separation by 
chromatography; (b) MOMCl, i-Pr2NEt, CH2Cl2, rt, 3 hr; (c) 1. LiAlH4, THF, rt, 30 min; 2. PivCl, py, rt, 1 
hr; (d) PPTS, MeOH, reflux, 3 hr; (e) NaIO4, MeOH, rt, 3 hr; (f) PPTS, t-BuOH, reflux, 2 hr; (g) Ag2CO3-
Celite, PhMe, reflux, 2 hr; (h) TMSBr, CH2Cl2, -15 °C, 3 hr; (k) ClCSOPh, py, DMAP, MeCN, rt, 1h; (i) 
n-Bu3SnH, AIBN, PhMe, reflux, 1 hr; (j) LHMDS, ArCH2Br, THF, -75 °C, 1 hr; (l) 1M aq. NaOH, EtOH, 
rt, 16 hr; then 6M aq. HCl (twice). Ar=Ar5 (for Ar see Appendix 1). 
 
3.3.4 Miscellaneous mechanisms 
 
Mäkelä et al.93 were the first to accomplish the total synthesis of (7'R*,8R*,8'R*)-7'-
hydroxymatairesinol 15 and (7'S*, 8R*,8'R*)-7'-hydroxyenterolactone 7. The 7' epimers were 
separated by semi-preparative HPLC and fully characterised, but because at that time the 
absolute configuration of this type of lignan had not yet been definitely assigned, the C-7' 
stereochemistry was erroneously allocated based on the available literature.89,90 The 
dithiophenol 100, prepared by a modification of the tandem Michael addition-alkylation 
protocol, fashioned by Ziegler and Schwartz186 and developed by Pelter et al.,187 was 
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converted to a ketone, in turn reduced to a 3:2 mixture of isomers separated 
chromatographically.  
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Scheme 53. Reagents and conditions: (a) HgO, BF3·Et2O, THF-H2O, rt, 4 hr; (b) H2, Raney nickel, 
EtOH, rt, 1h; separation by chromatography. Ar=Ar3→2, Ar10→7 (for Ar see Appendix 1). 
 
The strategy presented by Yoda and co-workers188,189 started from hydroxylactone 101190 
readily converted to a keto-amide 102, which was arylated using a Grignard reaction (de up 
to 99%).191 The monobenzyl compound furnished the target hydroxylactone after a 
protection-deprotection-cyclization series. Despite the fact that the authors had developed a 
diastereomeric separation to obtain enantiomerically pure Bn-protected 101,192 the synthesis 
was performed on the racemate. 
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Scheme 54. Reagents and conditions: for R=Bn: (a) 1. BnBr, Ag2O, EtOAc; 2. Me2NH, MeOH; (b) 
(COCl)2, DMSO, THF, then Et3N, -78 → -45 °C; (c) ArMgBr, THF, 0 °C; (d) 1. TIPSOTf, 2,6-lutidine, 
CH2Cl2; 2. H2, 5% Pd/C, MeOH; 3. PPTS, PhMe, 45 °C; for R=TBDPS: (a) 1. TBDPSCl, CH2Cl2, 
imidazole; 2. Me2NH, MeOH; (b) as before; (c) as before; (d) 1. BnBr, Ag2O, EtOAc; 2. TBAF, THF; 3. 
p-TsOH, PhMe. Ar=Ar5, Ar14 (for Ar see Appendix 1). 
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Uchiyama and co-workers193 developed this synthesis aiming to reproduce the natural 
compound (±)-arthrinone, a biologically active compound containing a semiquinone structure, 
and thus not to a lignan (Scheme 55). 2,3-Dihidrofuran 103 was converted to acetal 104 via a 
selenium intermediate. A stereoselective [2,3]-Wittig rearrangement of 104 furnished the 
primary alcohol which was transformed in 105, a suitable substrate for a regioselective 
Diels–Alder reaction with 106. The associated retro-Diels–Alder furnished the desired 
aromatic moiety of the benzyl-butyrolactone. 
 
a c
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Scheme 55. Reagents and conditions: (a) PhSeCl, CH2Cl2, TMS-2-propyn-1-ol, -78 → 50 °C; (b) 30% 
H2O2, NaHCO3, AcOEt, THF, 0 °C → rt; (c) n-BuLi, THF, -78 °C; (d) TBAF, THF, 0 °C → rt; (e) 
TBDPSCl, imidazole, DMF, rt; (f) n-BuLi, THF, -78 °C, then ClCO2Et, -78 °C → rt; (g) AcOH, THF, 
H2O, rt; (h) PCC, MS 4 Å, CH2Cl2, 0 °C → rt, (i) 106, 160 °C; then THF, 5% HCl. Ar=Ar20 (for Ar see 
Appendix 1). 
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4 Rearrangement reactions of hydroxylated lignanolactones under 
basic conditions 
 
In 1976, Nishiba et al.88 reported the formation of a mixture of two hydroxylactones during the 
deacetylation of naturally occurring acetylparabenzlactone 107 with KOH/MeOH (Scheme 
56). Spectroscopic data indicated that the two products were the expected deacetylated (–)-
parabenzlactone 25 and its structural isomer 108a. As discussed in Chapter 2, 25 was 
considered to possess the stereochemistry described in Scheme 56, this is to say 
(7'R,8R,8'R), and thus the same absolute configuration was attributed to 107. The 
regioisomer of 25, which was named isoparabenzlactone, was established to be a 
lariciresinol-type lignan, a structure reported only once before.87 Unfortunately, in the same 
way that the absolute configuration of (–)-parabenzlactone was erroneously assigned, an 
incorrect configuration (7',8'-cis-8,8'-cis, as that described in Scheme 56) was also attributed 
to the new lignan 108a. Investigations into the stereochemistry of these compounds and the 
assignment of the correct configuration will be discussed in chapter 5.2. In addition, the same 
group reported that treating what was then believed to be (7'S,8R,8'R)-7'-
acetylhydroxyarctigenin monoacetate (7'S)-109 with similar basic conditions, no 
rearrangement occurred (Scheme 56), but no explanation was given for this behaviour.21 
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Scheme 56. Saponification of (7'R)-acetylparabenzlactone 10788 and (7'S)-7'-acetylhydroxyarctigenin 
monoacetate 10921 as reported by the authors. As it will be discussed in section 5.2, the configurations 
of the molecules (starting materials and products) are incorrect. Ar=Ar5, Ar'=Ar9, Ar''=Ar24, Ar'''=Ar7 (for 
Ar see Appendix 1). 
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During their investigation on the reactivity of 7'-hydroxymatairesinol 15, Eklund et al.194 found 
that a mixture of such diastereomers in alkaline/THF solution (pH 8-9) furnished, along with 
the other products, two rearranged lactones (Scheme 57) identified as the two isomers  
7',8'-trans-8,8'-cis 110 and 7',8'-cis-8,8'-cis 108b. The outcome of the reaction is strictly 
connected to the starting material 7'-hydroxymatairesinol 15 and to the particular mechanism 
involved. On the basis of some evidence, the authors proposed the formation of a para-
quinone methide as intermediate in the rearrangement reaction,195 which is made possible by 
the free para-hydroxyl group of the starting material 15. In this way, depending on which face 
the carboxylic acid anion approached the 7' position (route a or b, Scheme 57), both 
rearranged lactones could be formed (with a preference for the 7',8'-trans isomer 110, due to 
geometric reasons). The outcome of the rearranged lactones in this case does not depend 
on the stereochemistry at 7' of 15, as with the quinone methide mechanism, 7' loses its 
chirality prior to when the rearrangement occurs. It was observed, however, that (7'S)-15 
reacted more easily than the R isomer. In addition, Eklund reported that under Nishibe’s 
conditions (2% KOH/MeOH) 7'-hydroxymatairesinol 15 furnished a small amount of 7'-
methoxymatairesinol 111, as a result of the nucleophilic attack of methanol to the quinone 
methide intermediate.194 Therefore the reactivity of 15 is strictly dependent on the structure of 
the molecule and, in particular, on the presence of the para-OH. 
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Scheme 57. Rearrangement of 7'-hydroxymatairesinol 15 in aqueous alkaline conditions.194 Ar=Ar7 
(for Ar see Appendix 1). 
 
Iwasaki’s group in order used the rearrangement reaction to obtain a suitable stereoisomer 
capable of being stereoselectively alkylated and to provide, after a reduction followed by a 
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lactone ring reinstallation, 8-alkyl- or 8-OH-lignano-9,9'-lactones.196,197 Thus the racemic 
mixture of (±)-112 was treated with NaH/DMF, giving a rearranged lactone as the only 
product in more than 75% yield (Scheme 58). During the rearrangement reaction, the 
epimerization at C-8 occurred to yield the thermodynamically more favourable 7',8'-trans-8,8'-
trans product (±)-113 (all-trans). 
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Scheme 58. Rearrangement of (±)-112 in NaH/DMF to yield (±)-113 as only product.196,197 Ar=Ar5, Ar9; 
Ar'=Ar5, Ar9, Ar10 (for Ar see Appendix 1). 
 
As briefly discussed in the previous chapter (Scheme 52), Yamauchi31,185 used the 
translactonization reaction to access a cis-8,8' lignan, which is difficult to obtain with other 
strategies. Compared to the rearrangements observed above, this one starts from the 
optically pure trisubstituted 7',8'-cis-8,8'-trans-lignano-9,7'-lactone 114, which upon treatment 
with aq. NaOH in MeOH, gives the deprotected 7',8'-cis-8,8'-trans-lactone 115 and the 
rearranged 8,8'-cis (7'R)-7'-hydroxylignano-9,9'-lactone (7'R)-116 in 49 and 25% yield 
respectively (Scheme 58). Upon an additional treatment of 115 with aq. NaOH/EtOH, (7'R)-
116 was obtained in a further 31%, while the starting material 116 was recovered in 69% 
yield. No side reactions (e.g. epimerization) were reported. 
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Scheme 59. Rearrangement of lactone 114 in aq. NaOH/EtOH. After two basic treatments 115 was 
obtained in 41% yield and (7'R)-116 in 34%. Ar=Ar5, Ar10 (for Ar see Appendix 1). 
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After this excursus, it is acknowledged that 7'-OH-lignano-9,9'-lactones and 9'-OH-lignano-
9,7'-lactones can rearrange into each other under various basic hydrolytic conditions. The 
outcome of the reaction depends on the starting material (structure, stereochemistry and Ar 
substituents, like in the peculiar case of 7'-OH-matairesinol 15) and on the reaction 
conditions. As will be discussed in detail in the next part of the thesis, our investigations on 
this subject revealed some errors in the published literature which could be rectified. At the 
same time, some mechanistic aspects concerning the intramolecular translactonization of 
these kinds of compounds will also be discussed and clarified. 
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5 Aim of the study 
 
Our interest in lignans, and in 7'-OH-lignano-9,9'-lactones in particular, originated from the 
possible biological effects of these compounds and by the fact that, despite the number of 
various methods discussed in the sections above (chapter 4), only few syntheses of  
7'-OH-lignano-9,9'-lactones were available in the literature when this project started. These 
methods were not stereoselective, or needed certain requirements (particular aromatic 
substituents, certain starting materials’ configuration) that would not allow a general synthetic 
approach. The lack of synthetic protocols was one of the reasons why the knowledge about 
7'-OH-lignano-9,9'-lactones was still limited (for example the absolute configuration had not 
been definitely determined) and the situation was worsened by the conflicting and wrong 
data reported in the literature. Thus the main task of this project was to develop a general 
procedure for the stereoselective synthesis of 7'-OH-lignano-9,9'-lactones that allows the 
eventual production of both optically pure trans-(8R,8'R) and trans-(8S,8'S) isomers, and 
could be flexible in regard to the aromatic substitution patterns (i.e. not only naturally 
occurring substituents). During the optimization of this synthetic protocol, several problems 
were encountered and new challenges appeared along the way. The unexpected 
rearrangement reaction with L-Selectride® and the re-assignment of the configuration of  
(–)-parabenzlactone drove our interest in the study of rearrangement reactions in basic 
conditions. Being aware that some published data were incorrect, we also aimed to clarify 
and harmonize these conflicting data, especially concerning the stereochemistry and 
reactivity of 7'-OH-lignano-9,9'-lactones. Thus, the mechanism of the rearrangement of 
hydroxylignanolactones in basic conditions was investigated. In addition, the absolute 
configuration of two lignan regioisomers was also definitely proven by X-ray spectroscopy. In 
particular, the X-ray structures of 7'-OH-lignano-9,9'-lactones were obtained for the first time. 
A parallel project, connected to an international consortium study on lignans, phytoestrogens, 
and human health, concerned the synthesis of new possible mammalian lignan metabolites, 
for a possible use as reference material in metabolic and biology studies (for example as 
deuterated derivatives). 
In this chapter, the aromatic substituents will be indicated as described in Appendix 1. 
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5.1 Stereoselective synthesis of 7'-hydroxylignano-9,9'-lactones 
 
5.1.1 The construction of the (8R,8'R)-lignano-9,9'-lactone framework 
 
To fashion the lignan skeleton, the tandem Michael addition-alkylation reaction was chosen 
because our laboratory had a long experience with this type of protocol (for racemic lignano-
9,9'-lactones as well as 7'-hydroxy derivatives),93 and also because the reaction exhibited 
shortness, versatility, and sturdiness: the desired requirements in this synthesis. Optically 
pure 7'-OH-lignano-9,9'-lactones were obtained using the asymmetric tandem Michael 
addition-alkylation reaction, pioneered by Feringa’s and Wards' groups.198,199 The 
stereoselectivity of the tandem reaction was controlled by the chiral Michael acceptor  
(5R)-(–)-menthyloxy-2(5H)-furanone (5R)-117 (Fig. 13)200 which furnished the trans-(8R,8'R) 
lactone. The 5S isomer would eventually provide the less common trans-(8S,8'S) isomer.  
 
O
O
O
O
O
O
R S
(5R)-117 (5S)-117  
Fig. 13. (5R)-(–)-menthyloxy-2(5H)-furanone (5R)-117 and its isomer (5S)-117. 
 
Heartened by the reported positive results,197,201,202 initially an asymmetric tandem Michael 
addition-alkylation was attempted using a silyloxy-nitrile 118 as nucleophile (Scheme 60). 
This approach, however, was not satisfactory due to the silyloxy-nitrile hydrolysis and the 
reduction of the formed ketone occurring during the menthyloxy removal step, which yielded 
a complex mixture of products that were difficult to handle. Therefore the dithiane 119 
(Scheme 60) was chosen as nucleophile, but in this case the tandem product resisted all 
attempts at removing the menthyloxy auxiliary. 
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Scheme 60. Reagents and conditions: (a) n-BuLi, THF, DMPU, -78 °C; (b) NaBH4, KOH, EtOH, 0 °C. 
Ar=Ar4 (for Ar see Appendix 1). 
 
Thus the Michael addition product 120 (Scheme 61) was submitted to basic hydrolysis 
conditions followed by the in situ NaBH4 reduction of the formed aldehyde to furnish the 
chiral lactones 121 on ordinary acidic workup.203 No isomerization was detected by 1H NMR, 
using the chiral shift reagent Eu(hfc)3 (ee ≥98%). The lignan skeleton was then completed by 
alkylation of 121 with the suitable benzylic bromides to get only the trans-(8R,8'R)-
lignanolactones 122.186 It is noteworthy that both steps a and c require the use of co-solvents 
DMPU and DMI respectively. 
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Scheme 61. Reagents and conditions: (a) n-BuLi, THF, DMPU, (5R)-117, -78 °C; (b) 1. KOH, NaBH4, 
EtOH, 0 °C; 2. 0.1N HCl (pH 5-6); (c) LDA or LHMDS, THF, DMI, Ar'CH2Br, -78 °C → rt; (for Ar see 
Appendix 1). 
 
5.1.2 The removal of the dithiane moiety and the reduction with L-Selectride 
 
The removal of the dithiane moiety proved to be a challenging task. In the search for a 
general method, which would not affect the aromatic substituents (e.g. silyl groups), several 
protocols to reinstate the ketone were tested.204,205 Attempts were initially made with mercury 
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salts as HgCl2–HgO, HgCl2–CaCO3, Hg(ClO4)2•3H2O–DIPA. Target compounds, but in a very 
low yield, due to the problems in the product purification, or unreacted starting material were 
obtained. In addition, the high toxicity of these reagents prompted the search for a more 
efficient alternative. Thus standard protocols using CuCl2–CuCO or MeI–CaCO3, and more 
recent protocols with NaNO2–AcCl,206 Dess-Martin periodinane207 or NaI–TaCl5–H2O2208 were 
tried but all attempts were inefficient. Finally, the ketone 123 was unmasked using the Stork–
Zhao209 method but with 3 eq. of (CF3CO2)2IPh (Scheme 62). The reaction proceeded very 
rapidly and the purification procedure did not pose any problems. The only drawback was the 
moderate yield (50 to 80%), however neither starting material nor side products (e.g. 
desilylated compound) were recovered from the workup mixture. 
With the 7'-oxolignanolactone 123 available, an easy access to the final target was 
anticipated by using L-Selectride (step b, Scheme 62). Previously reported results with 
racemic lignans197 and 7-OH lignans179 as substrates were encouraging. As expected, a 
hydride attack from the less hindered face of the ketone lead to 7'S products 25, 124 and 
112b-e, obtained in all cases with a high stereoselectivity. However, the reduction turned out 
to be more challenging than expected. Considerable dissimilarities in the outcome of the 
reduction were registered with de values ranging from 83 to 97% (Table 2). The de values 
were determined by 1H NMR and were based on the ratios between the H-7' signals (δ ≈ 4.6 
for the S isomer and δ ≈ 4.4 for the R isomer in CDCl3, irrespective of the aromatic 
substituents). The reasons for this variation are not immediately obvious, as the differences 
in structures reside at relatively remote locations (aromatic substituents). Earlier works do not 
report this kind of behaviour.179,197 It is worthwhile to mention that, if the spectra are 
registered in solvents other than CDCl3, the chemical shifts for these diagnostic signals are 
shifted. For example, in acetone-d6 the H-7' signal for the R isomer occurs at about δ 4.5 
(see Annex 2, Table 8), while for the S isomer at δ 4.8 (see Annex 2, Table 7). 
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Scheme 62. Reagents and conditions: (a) (CF3CO2)2IPh, MeCN-H2O, rt; (b) L-Selectride, THF,  
-78 °C; (c) TBAF/AcOH, THF, 0 °C; (for Ar see Appendix 1). 
 
Table 2. L-Selectride reduction of 123a-f. 
Entry Ketone Alcohol de (%)a δ (H-7'S) δ (H-7'R) Yield (%)b
1 123a 25 97 4.57 4.37 70 
2 123b 112b 93 4.62 4.38 75 
3 123c 112c 83 4.60 4.38 77 
4 123d 112d 88 4.53 4.35 68 
5 123e 112e 96 4.61 4.38 80 
6 123f 124 97 4.66 4.39 61 
(a) Determined by 1H NMR of crude products (CDCl3). (b) After flash chromatography (7'S + 7'R). 
 
The reduction with L-Selectride (followed by protecting groups removal, when necessary) 
provided the target (7'S)-7'-hydroxyenterolactone (7'S)-7 (a mammalian lignan, obtained for 
the first time in enantiopure form), (7'S)-7'-hydroxymatairesinol (7'S)-15, (7'S)-
parabenzlactone (7'S)-25, (7'S)-7'-hydroxyarctigenin (7'S)-27, (7'S)-7'-hydroxybursehernin 
(7'S)-124 and (7'S)-7'-hydroxyprestegane B (7'S)-125 (the last two not found in natural 
matrices yet). Spectroscopic data of (7'S)-7 were similar to those reported earlier by Mäkelä93 
for the racemic material. It must be noted, however, that our 7'S isomer corresponds to 
Mäkelä’s 7'R compound, as Mäkelä’s results were based on outdated and incorrect data. 
Spectroscopic data of (7'S)-15 and (7'S)-27 were in agreement with published data and 
supported the findings of Eklund91 and Fisher.94 Finally, spectroscopic data of (7'S)-25 
showed that the stereochemistry of naturally occurring (–)-parabenzlactone, and 
consequently of 7'-acetylparabenzlactone 107 (Scheme 56), had been erroneously assigned 
as 7'R. The unquestionable evidence of the absolute configuration of (7'S)-(–)-
parabenzlactone is given by the X-ray structures (Fig. 14). Also (7'S)-124 afforded crystals 
suitable for X-ray study. These are the first ever reported X-ray analyses for (7'S,8R,8R')-7'-
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OH-lignano-9,9'-lactones. Very close similarity can be observed for the two structures. In 
both crystals, the γ-butyrolactone ring presents a chair conformation with the C8 atom 
pointing below the lactone plane. In addition, the aromatic rings are in a folded conformation, 
which appears to be the less stable one in a recently published computer-based 
conformational study of 7'-hydroxymatairesinol.210 
 
Fig. 14. ORTEP plot of (7'S)-parabenzlactone (7'S)-25 (50% probability ellipsoids).  
 
 
Fig. 15. ORTEP plot of (7'S)-7'-hydroxybursehernin (7'S)-124 (50% probability ellipsoids). 
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Treatment with L-Selectride not only furnished the desired secondary alcohol, but also a 
byproduct that was identified as the rearranged lactone 126 (Scheme 62). In some cases this 
lactone was only detected by NMR, but in the cases of 126a, 126b, and 126f the products 
were isolated and characterized. The 7',8'-trans-8,8'-cis stereochemistry was assigned by 2D 
NMR (COSY and NOESY) and on the basis of the presumable mechanism of formation: a 
translactonization reaction where the 7'-alkoxyborane from the selectride reaction acted as 
nucleophile towards the lactone ring, with the formation of a primary alcohol as a 
consequence. This rearranged lactone was found to be a homochiral analogue of the major 
isomer 110 (7',8'-trans-8,8'-cis), one of the two lariciresinol-type lactones reported by Eklund 
shortly before,194 and obtained by a basic treatment of 7'-hydroxymatairesinol 15 (chapter 4, 
Scheme 57). Correlations between the spectroscopic data of 126a, 126b, 126f and 110 can 
be observed in Annex 2, Table 10. In particular, they all have a diagnostic signal for H-7'  
(δ ≈ 5.5, 3J7',8' = 2.0-2.6 Hz), which appears to be typical for this configuration. Thus, even if 
two different mechanisms of formation are involved (simple transesterification for 126 and via 
a quinone methide for 110), the two molecules have the same stereochemistry. The absolute 
configuration of the rearranged product was definitely established by X-ray analysis of 126a 
(Fig. 16). In addition, compound 126b was converted to 110 and the spectroscopic data were 
in agreement with those reported by Eklund.194 Compound 110 was also established to be a 
naturally occurring lignan as well and not only a synthetic product.194  
 
Fig. 16. ORTEP plot of the rearranged lactone 126a (50% probability ellipsoids), obtained as side 
product in the L-Selectride reduction of 123a. 
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Additional studies on the L-Selectride reaction, using 123a as substrate, showed that 
increasing the amount of reagent, the rearranged product 126a increased at the expense of 
(7'S)-25 (Table 3). However, the reasons for this behaviour are not yet disclosed and studies 
are still ongoing in our laboratory. 
 
Table 3. Outcome of the reduction of 123a with increasing amount of L-Selectride 
Entry eq. of L-Selectride Ratio(7'S)-25:126aa 
1 1.1 82:18
2 5 69:31 
3 10 53:47 
(a) determined by 1H NMR of the crude material. 
 
5.2 Rearrangement and stereochemistry studies 
 
The reassignment of the stereochemistry of naturally occurring (–)-parabenzlactone 25 and 
7'-acetylparabenzlactone 107 as 7'S (thus different as described in Scheme 56), also 
involved a re-examination of the lignano-9,7'-lactone 108a obtained from the treatment of 
(7'S)-107 with 2% KOH/MeOH and originally described with a 7',8'-cis-8,8'-cis configuration 
(all-cis, Scheme 56).88 Based on the corrected stereochemistry of (7'S)-107, the rearranged 
product obtained by a simple translactonization should be the 7',8'-trans-8,8'-cis isomer 
126a, but the reported NMR data of 108a88 (in particular the 7'-H signal, doublet at δ 5.13,  
3J7',8' = 8 Hz) are not well-matched with those obtained for compound 126a (doublet at δ 5.45, 
3J7',8' = 2.6 Hz) in the L-selectride reduction. It was noticed, however, that the 1H NMR data of 
108a (7'-H doublet at δ 5.12, 3J7',8' = 9.3 Hz) were in fact consistent with those of 108b, the 
7',8'-cis-8,8'-cis minor rearranged lactone reported by Eklund et al.194 (chapter 4, Scheme 
57), which has the H-7' signal at about δ 5.1, 3J7',8' = 9.3 Hz. Because an all-cis configuration 
could only be obtained from an inversion at 7', it was considered that, in competition with the 
acetate hydrolysis and thus the formation of (7'S)-25, the lactone may also undergo 
hydrolysis with the formation of a primary alcohol and a carboxyl group (Scheme 63). The 
COO generated in basic conditions can act as a nucleophile and attack the 7' center via a 
SN2 mechanism, with simultaneous detachment of the AcO group. The final result would be a 
new lactone ring with inversion of configuration at the 7' position (Scheme 63). One should 
notice that for acetylparabenzlactone, mere AcO hydrolysis is not sufficient to trigger the 
lactone rearrangement, and no other rearranged lactones were mentioned in Nishibe’s 
paper.88 In addition, the stereochemistry at 7' should be such that the approach of COO is 
allowed, thus giving a possible explanation as to why (7'R)-7'-acetylhydroxyarctigenin 
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monoacetate (7'R)-109 (the stereochemistry of this compound had been erroneously 
assigned as in Scheme 5621 and should have been 7'R as described in Scheme 63) failed to 
furnish the rearranged lactone. 
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Scheme 63. Possible mechanism of formation of 108a from (7'S)-acetylparabenzalctone (7'S)-107. 
Ar=Ar5; Ar'=Ar9; Ar''=Ar24; Ar'''=Ar7 (for Ar see Appendix 1). 
 
5.2.1 Translactonization of 18O-labeled substrates 
 
To verify whether this mechanism could be plausible some studies were pursued using  
18O-labeled compounds and monitoring the results by mass spectroscopy (MS).  
To distinguish between the simple translactonization and the SN2 rearrangement mechanism, 
the labeled (7'S)-7'-18O-acetylhydroxylignanolactone (7'S)-18O-107 was prepared and 
assessed by MS for the conservation vs. loss of the label. In the simple translactonization 
route, the 18O should be retained in the product, but should be missing in the rearranged 
lactone derived by the SN2 mechanism. The 18O label was introduced during the deprotection 
of the dithiane moiety of 122 using H218O as co-solvent (Scheme 64). The treatment of  
18O-123a,b with L-Selectride furnished, as expected, the (7'S)-18O-25 and (7'S)-18O-112b 
along with the rearranged 9,7'-lactones 18O-126a,b in a ca. 85:15 ratio (Scheme 64). The MS 
spectra showed that the 18O label was totally conserved in the rearranged lactone18O-126, as 
anticipated for a simple translactonization (L-Selectride reduction). The acetylated (7'S)-18O-
107 was submitted to hydrolytic conditions and a mixture of (7'S)-18O-25 and rearranged 
lactone was obtained in a ca. 60:40 ratio. However the MS analysis of the latter compound 
showed that the molecule still contained the 18O label. This result was in conflict with a 
possible SN2 mechanism, which was therefore ruled out. Moreover, a simple 
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translactonization would have furnished the product obtained by L-Selectride 18O-126 and 
easily distinguished from the hydrolysis product 18O-25, thanks to the diagnostic 7'-H NMR 
signal. Finally, a careful examination by MS and 2D NMR revealed that this material is the 
7',8'-trans-8,8'-trans isomer (all-trans) 18O-113a (Scheme 64), which arose from a 
translactonization accompanied by an α-epimerization. This material is the chiral version of 
(±)-113 obtained before by Iwasaki after treating (7'S*,8R*,8'R*)-7'-hydroxylignanolactone 
(±)-112 with NaH/DMF,196,197 and discussed earlier in Scheme 58. Thus, the coincidental 
NMR resemblance between the all-cis 108b and the all-trans 113a lactones (see Appendix 2) 
erroneously lead us to the wrong SN2 mechanism proposal. (±)-113a has been previously 
reported in unlabeled form.211  
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Scheme 64. Reagents and conditions: (a) (CF3CO2)2IPh, MeCN/H218O, rt; (b) L-Selectride, THF,  
-78 °C; (c) Ac2O-py, rt; (d) 2% KOH/MeOH, rt. For a Ar=Ar5, for b Ar=Ar11 (for Ar see Appendix 1). 
 
The absolute configuration of 113a was confirmed by X-ray analysis of the  
3,5-dinitrobenzoate derivative 127 (Fig. 17). 
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Fig. 17. ORTEP plot of 127 (50% probability ellipsoids). 
 
5.2.2 Translactonization studies with NaH/DMF and KOH/MeOH 
 
Due to the similarity (as for the stereochemistry) in the outcome using different reaction 
conditions (NaH/DMF and 2% KOH/MeOH), it was interesting to directly compare the two 
translactonization/α-epimerization reactions. Thus (–)-parabenzlactone (7'S)-25 was 
submitted to both Nishibe’s88 and Iwasaki’s197 rearrangement conditions. The KOH/MeOH 
reaction furnished, as expected, a mixture of starting material (7'S)-25 and rearranged 
lactone 113a in a ca. 60:40 ratio, as observed for the hydrolysis of (7'S)-18O-107 (Scheme 
64). Surprisingly, in our hands, a mixture of the starting material (7'S)-25 and the rearranged 
all-trans lactone 113a in a ca. 40:60 ratio was furnished also by NaH/DMF. This proved, 
therefore, to be very different from Iwasaki’s results, that showed a 75% yield and neither 
recovery nor detection of starting material reported.197 To exclude any effects due to the 
unlike aromatic substituents, Nishibe’s and Iwasaki’s rearrangement conditions were used on 
the enantiopure compound (7'S)-7'-hydroxybursehernin (7'S)-124 (whilst Iwasaki was using 
the racemic mixture) as substrate. With NaH/DMF (7'S)-124 gave results comparable to 
those obtained for (7'S)-25 for both yield and ratio between the starting material and the 
rearranged lactone (Table 4). As expected, the nature of phenolic protection did not play a 
role in these reactions. 
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Scheme 65. Reagents and conditions: (a) 2% KOH/MeOH, rt; (b) NaH/DMF, 0 °C; (for Ar see 
Appendix 1).  
 
Table 4. Outcome of the reaction described in Scheme 65. 
Reagents Ratio of products(7'S)-25:113a (7'S)-124:113f 
2% KOH/MeOH 64:36 57:43 
NaH/DMF 40:60 36:64 
 
The difference in the predominant product obtained under Nishibe’s and Iwasaki’s conditions 
may be explained by the reaction mechanisms. When NaH/DMF is employed, the lactone 
moiety of (7'S)-25 undergoes a nucleophilic attack by the formed alkoxide ion and the α-
epimerization occurs more or less simultaneously to give the thermodynamically more stable 
all-trans product 113a (Scheme 66).  
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Scheme 66. Mechanism of translactonization/α-epimerization of (7'S)-25 in NaH/DMF. Ar=Ar5 (for Ar 
see Appendix 1). 
 
In the case of KOH/MeOH (Scheme 67), the lactone moiety of (7'S)-25 undergoes 
transesterification by the action of methoxide present in the reaction medium, forming the 
methyl ester diol intermediate, which can be deprotonated at the α position. After 
acidification, relactonization can occur with either hydroxy group present in the intermediate, 
but the preference is determined by the selectivity of α-proton reinsertion into the molecule, 
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prior to relactonization. A reprotonation from the less hindered upper face leads back to the 
starting material (7'S)-25, whereas protonation from the lower face will lead to the rearranged 
113. From the (7'S)-25:113a ratio values, it is clear that the structure (7'S)-25 is preferred. 
Evidence for this equilibrium was obtained by treating 113a with 2% KOH/MeOH. 
Translactonization/α-epimerization is observed and the ratio (7'S)-25:113a = 66:34 was 
obtained after 48 hours (compared to 1.5 hours required when (7'S)-25 was the starting 
material). The 9,7'-lactone 113a is probably more hindered than (7'S)-25, making 
transesterification less favorable. Furthermore, when (7'S)-25 and 113a were treated with 2% 
KOH/t-BuOH, no rearrangement was observed. 
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Scheme 67. Mechanism of translactonization/α-epimerization in 2% KOH/MeOH. Ar=Ar5 (for Ar see 
Appendix 1). 
 
5.2.3 Translactonization studies with aq. NaOH/EtOH 
 
The translactonization conditions used to obtain the unnatural (7'R,8S,8'R)-8,8'-cis-
parabenzlactone (7'R)-116 from 7',8'-cis-8,8'-trans-lignano-9,7'-lactone 114 or 115 (aq. 
NaOH/EtOH, Scheme 59)185 were tested on the 7',8'-trans-8,8'-trans 113a in order to check 
whether it was possible to obtain the 7'S isomer of (7'S)-116 (Scheme 68). Unfortunately no 
translactonization was observed and only the starting material was recovered. Since the only 
difference between our and Yamauchi’s reaction can be found in the stereochemistry at the 
7' site of the starting material, it is likely that this must play a crucial role in the formation of 
an all-cis 7'-hydroxylignano-9,9'-lactone. To confirm that steric hindrance is a key feature in 
these types of reaction, also (7'S)-25 was treated with 1M aq. NaOH/EtOH (Scheme 68). As 
expected, also in this case no rearrangement product (126a) was observed. Thus for 
substrates with stereochemistry like 113a and (7'S)-25, a rearrangement in basic hydrolytic 
conditions is allowed only with an α-epimerization (Scheme 67), which is not observed in aq. 
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NaOH/EtOH. In support of these considerations, 113a and (7'S)-25 were further treated with 
2% aq. KOH/MeOH (50:50) and again only starting material was obtained.  
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Scheme 68. Reagents and conditions: (a) 1. 1M aq. NaOH, EtOH (or 2% aq. KOH, MeOH), rt; 2. 2N 
HCl. Ar=Ar5 (for Ar see Appendix 1). 
 
5.2.4 Translactonization studies of (±)-8-methylparabenzlactone 
 
To discriminate between the role of the stereochemistry at 7' and that of α-epimerization, 
translactonizations under basic conditions were further tested on (±)-8-
methylparabenzlactone 128a (Scheme 69). Lactone 128a, a compound where no α protons 
are available, was synthesized with the Michael addition–alkylation protocol using 129 as 
Michael acceptor. The reduction of ketone 130 with L-Selectride furnished as expected (±)-
(7'S)-8-methylparabenzlactone 128a (de 99%) and the 7',8'-trans-8,8'-cis translactonization 
product 131a in a ca. 84:16 ratio (Scheme 69). Lactone 128a was subjected to the various 
conditions discussed in chapter 5.2.2 and 5.2.3 (2% KOH/MeOH, NaH/DMF and 1M aq. 
NaOH/EtOH), and furnished, in all cases, the starting material and the rearranged product 
131a in a ca. 65:35 ratio. Thus the presence of the methyl group at C-8 clearly affects the 
behaviour of the rearrangement reaction. In the case of 1M aq. NaOH/EtOH, the presence of 
the water in the reaction medium does not prevent (as seen for (7'S)-25, Scheme 68) the 
reaction from occurring, providing the same ratio as with 2% KOH/MeOH, in turn comparable 
with those obtained for (7'S)-25 and (7'S)-124. On the other hand, NaH/DMF furnished less 
rearranged lactone 131a when compared with the results obtained with (7'S)-25 and (7'S)-
124 (where the ratio starting material/rearranged product was 40:60), likely due to steric 
hindrance exerted by the 8-methyl in the nucleophilic attack and by the 8,8'-cis configuration 
of the product. 
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Scheme 69. Reagents and conditions: (a) n-BuLi, THF, DMPU, -78 °C; (b) LHMDS, THF, DMI, 
ArCH2Br, -78 °C → rt; (c) (CF3CO2)2IPh, MeCN-H2O, rt; (d) L-Selectride, THF, -78 °C; (e) 1. 2% 
KOH/MeOH, rt; 2. 2N HCl; (f) 1. NaH/DMF, 0 °C; 2. 2N HCl; (g) 1. 1M aq. NaOH, EtOH, rt; 2. 2N HCl. 
Ar=Ar5 (for Ar see Appendix 1). 
 
5.2.5 Translactonization studies of Ar-O-silylated (7'S)-7'-hydroxymatairesinol 
 
In connection with another study, we have observed that phenolic silyl ethers can be cleaved 
selectively in the presence of aliphatic silyl ethers by means of NaH in DMF.212 Thus the aryl-
O-silyl protected (7'S)-7'-hydroxymatairesinol (7'S)-112b (see Scheme 62) was subjected to 
the NaH/DMF translactonization conditions (Scheme 70). As anticipated the reaction proved 
to be a powerful desilylating tool, and the all-trans rearranged/α-epimerized product with free 
phenolic groups 113c was obtained. However, the major product of this reaction was the 
unexpected TBDMS-derivative 132 formed by a migration of the silyl group to the aliphatic 
hydroxyl (Scheme 70). Traces of totally and partially silyl protected starting material were 
also detected by NMR, but were not isolated. The combined yield of rearranged lactones 
113c and 132 is higher than the yield of the rearranged lactones obtained by us from (–)-
parabenzlactone (7'S)-25 and (7'S)-7'-hydroxybursehernin (7'S)-124 under the same reaction 
conditions, but is in line with the original results obtained by Iwasaki on (±)-112 (Scheme 
58).197 The difference in the outcome of the reaction could not be explained. Maybe a retro-
translactonization is also involved in the reaction with NaH/DMF and additional investigations 
in this respect would be necessary. 
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Scheme 70. Reagents and conditions: (a) 1. NaH/DMF, 0 °C; 2. 2N HCl. Ar=Ar11; Ar'=Ar7 (for Ar see 
Appendix 1). 
 
As can be observed in Table 9 (Annex 2), the 1H NMR spectra of all-trans lignano-9,7'-
lactones 113a, 113b, 113c, 127, and 132, as well as of reported MOM protected lactones 
133a-c,197 show close resemblance, particularly regarding the diagnostic peak of H-7'. A 
similar behaviour can also be observed for 7',8'-trans-8,8'-cis-lignano-9,7'-lactones 126a, 
126b, 126f and 110 (Table 10, Annex 2), as well as for 7',8'-cis-8,8'-trans-lignano-9,7'-
lactones 114 and 115 reported by Yamauchi185 (Table 11, Annex 2). It is interesting to notice 
that regardless of the presence of a free or a protected alcohol (TBDMS, MOM, Piv) there 
are no remarkable differences in the NMR spectra of homochiral lignans. This feature can be 
useful in determining the stereochemistry of stereorelated trisubstituted lignano-9,7'-lactones, 
as it was possible for 7'-HO-lignano-9,9'-lactones (Table 7 and Table 8, Annex 2). Also in the 
case of 8-alkylated lignano-9,7'-lactones, there is a correlation between the 1H NMR spectra 
of 128a and of the other reported 128b,c197 all possessing a 7',8'-trans-8,8'-cis configuration 
(see Table 13, Annex 2). However, NMR correlations may not be possible for the all-cis 
stereoisomers. In fact, the only two all-cis lignano-9,7'-lactones that have been reported to 
date, 108b194 and (±)-134211 (Fig. 18), present a different 1H NMR spectrum in both chemical 
shifts and coupling constants (Table 12, Annex 2). As an example, the diagnostic peak of H-
7' is found at δ 5.12 (3J7',8' = 9.3 Hz) for 108b and at δ 5.43 (3J7',8' = 5.4 Hz) for (±)-134. The 
sizeable variation of these values could be caused by the bulky TBDMS group which may 
significantly affect the conformation in case of 7',8'-cis-8,8'-cis-lignano-9,7'-lactones (not 
observed for the other configurations). Surprisingly, the spectroscopic data ([α], 1H and 13C 
NMR) of 108b and of the all-trans isomers show notable similarity (see Table 9 and Table 12, 
Annex 2) and one could speculate if the Eklund’s all-cis lignan 108b possesses that 
configuration or if it is, in fact, the all-trans stereoisomer. In his paper Eklund presented 
convincing evidence (NOESY study, mechanism of formation) that the minor rearranged 
lactone is the all-cis lignano-9,7'-lactones 108b.194 In addition, the tentatively identification of 
the 8-epimer of 110 (that is to say the all-trans 113c) in the extractives of Norway spruce 
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knots was reported. Thus, the resemblance of spectroscopic data between the all-trans 113 
and all-cis 108b should be seen just as an accidental coincidence. 
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Fig. 18. Known 7',8'-cis-8,8'-cis-lignano-9,7'-lactones.194,211 Ar=Ar7; Ar'=Ar5 (for Ar see Appendix 1). 
 
A summary of the basic reactions of lignanolactones is presented in Appendix 3. 
 
5.3 Synthesis of potential mammalian metabolites of lignans  
 
After the discovery that, in addition to matairesinol 9 and secoisolariciresinol 10 and their  
O-glucosides (Fig. 9), several other plant lignans could be converted to mammalian lignans 
(or enterolignans) by the metabolic action of intestinal microflora,48,49 interest grew in the 
study of these new precursors, on their intake, on the possible metabolism and metabolites. 
Present interest is focused on developing lignan databases to estimate the lignan content of 
food (fruits, vegetables, cereals, whole grain products, beverages such as wine, beer, tea 
and coffee) and lignan intake in various populations.213 The plant lignans found to be 
precursors of enterolignans and thus under investigation, include pinoresinol 11, lariciresinol 
12 (Scheme 1), 7'-hydroxymatairesinol 15, syringaresinol 135, medioresinol 136, and 
arctigenin 137 (Fig. 19).48,49 
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Fig. 19. Additional naturally occurring precursors of mammalian lignans. 
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These studies on the new precursors have also led to the detection of previously unknown 
metabolic products. Unfortunately, the small amount of the products and the lack of authentic 
reference compounds often made the identification and the quantification of these new 
metabolites impossible. For example, the degradation of syringaresinol and medioresinol 
produced several compounds whose possible structure was postulated by Heinonen et al. on 
the basis of the mass spectra.48 These new metabolites should possess a 
dibenzylbutyrolactone- or a dibenzylbutanediol-type structure with variation concerning the 
presence and position of OH and OMe in the aromatic rings (Fig. 20). Authentic reference 
compounds are required to establish the structures of these potential new metabolites, thus 
we challenged the synthesis of several of the postulated metabolites presented in Fig. 20. 
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Fig. 20. Structures of the postulated metabolites of syringaresinol 135 and medioresinol 136.48 
 
The new (±)-trans-dibenzylbutyrolactones 138a-g were prepared by a modification of the 
tandem Michael addition–alkylation procedure.186,187,214 The protected dithioacetals 139a–g 
were obtained by reacting the acyl anion equivalents 140a-e with 2-butenolide 141 followed 
by in situ alkylation with appropriately substituted benzylic bromides 142a-e. In this case, the 
presence of co-solvent DMI is also essential for the reaction to succeed. Treatment of 139a-
g with Raney nickel provided desulfurization and simultaneous removal of the benzylic 
protecting groups to afford the desired dibenzylbutyrolactones (±)-138a-g. The new 
dibenzylbutanediols (±)-143a-f were obtained by reducing lactones 138a-f with LiAlH4. 
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Scheme 71. Reagents and conditions: (a) n-BuLi, THF, DMI, -78 °C; (b) Raney nickel, EtOH, refl. 3-10 
hr; (c) LiAlH4, THF, rt, 2-12hr; (for Ar see Appendix 1). 
 
In the tandem reaction, ortho- and meta-substituted aromatic starting materials (in particular 
when benzyloxy groups are present in both meta positions) reacted less readily providing 
only a satisfactory yield, presumably due to steric reasons. Optimum yields were obtained 
using highly concentrated solutions of starting materials in THF. The crucial step in the 
three–component reaction is undoubtedly the alkylation step. In the majority of cases, 
unreacted Michael addition products were recovered in up to 30% yield while only small 
amounts of diphenylthioacetals 140a-e were isolated. It was observed that for a better yield 
the addition of the benzylbromide to the reaction mixture should be done relatively quickly 
after the addition of butenolide 141. Lactones (±)-138a–g and diols (±)-143a–f were fully 
characterized by IR, mass, and NMR spectroscopy. Two-dimensional NMR experiments 
(COSY, HSQC and HMBC) were used to unequivocally allocate the 13C signals. 
Subsequently, some of the synthesised (±)-trans-dibenzylbutyrolactones were deuterated in 
order to be used as internal standards in analytical studies.215 
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6 Conclusions 
 
In this thesis a general asymmetric synthesis for obtaining optically active (7'S)-7'-
hydroxylignano-9,9'-lactones was developed. The interest in these types of lignans is due to 
their possible biological effects. The optimized protocol allowed the preparation of several 
compounds: (7'S)-7'-hydroxyenterolactone (7'S)-7 (a mammalian lignan, obtained for the first 
time in enantiopure form), (7'S)-7'-hydroxymatairesinol (7'S)-15, (7'S)-parabenzlactone (7'S)-
25, (7'S)-7'-hydroxyarctigenin (7'S)-27, (7'S)-7'-hydroxybursehernin (7'S)-124, and (7'S)-7'-
hydroxyprestegane B (7'S)-125. With the X-ray of (7'S)-25 and (7'S)-124, reported for the first 
time, it was possible to establish the absolute configuration of these stereoisomeric lignans 
and thus demonstrate that the reported configuration for the 7' position of naturally occurring 
(–)-parabenzlactone was incorrect. During the reduction with L-Selectride, a rearranged 7',8'-
trans-8,8'-cis-lignano-9,7'-lactone was formed as a byproduct, likely by a translactonization 
mechanism. The absolute configuration was determined by X-ray crystallography. Similar 
lactones, but with different stereochemistry and different mechanism of formation, were 
reported in literature. As a result, the rearrangement reactions of various hydroxylignano-9,9'- 
and 9,7'-lactones were investigated. Studies with 18O labeled substrates showed that our 
presumed mechanism of formation was erroneous and the absolute stereochemistry of the 
rearranged lactone obtained by treating (7'S)-7'-acetylparabenzlactone with 2% KOH/EtOH 
was determined to be 7',8'-trans-8,8'-trans by X-ray analysis of its dinitrobenzoate derivative. 
This compound was derived from a translactonization accompanied by an α-epimerization. 
Different basic conditions were evaluated showing that the stereochemistry of the lactone 
and the possibility of an α-epimerization determine whether a rearrangement is observed or 
not. Rearrangement studies were also performed on an 8-methyl substituted lignanolactone. 
In this case the stereochemistry was not decisive for the formation of the rearranged lactone, 
which was obtained under all conditions. Finally, the treatment of an aromatic silyl protected 
lignan with NaH/DMF, furnished a concomitant rearrangement, α-epimerization and aryl silyl 
deprotection, together with an unexpected migration of the silyl to the aliphatic hydroxy 
group. The resemblance observed in the 1H NMR for hydroxylignano-9,9'- and -9,7'-lactones 
can be a useful expedient for the assignment of the stereochemistry. 
In a parallel project, several new dibenzylbutyrolactones and dibenzylbutanediols were 
prepared, in two and three steps respectively, from aromatic starting materials. The new 
compounds were fully characterized by mass and NMR spectroscopy. The aromatic patterns 
of the new compounds were based on the postulated metabolites derived from the newly 
identified mammalian lignan precursors syringaresinol and medioresinol. These new 
 94
synthetic compounds could be used in the identification of new mammalian lignan 
metabolites, as well as in other biological or metabolic studies. 
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7 Experimental part 
 
The synthesis of (7'S)-7'-hydroxybursehernin (7'S)-124, and its spectroscopic data, are 
included in paper II. The X-ray data (not included in the original articles I-IV) are presented in 
this section. 
 
(7'S)-7'-hydroxybursehernin, (7'S)-124,  
(7'S,8R,8'R)-7'-hydroxy-3',4'-dimethoxy-3,4-methylenedioxylignano-9,9'-lactone 
 
Table 5. Crystal data and structure refinement of (7'S)-124, (Fig. 16). 
Empirical formula C21H22O7 
Formula weight  386.39 
Temperature 150(2) K 
Wavelength 1.54184
Crystal system monoclinic 
Space group P21 
Unit cell dimensions a=8.3530(3) 
b=6.4972(6) 
c=16.9997(7) 
alpha=90.018(5) 
beta=92.987(3) 
gamma=90.016(5) 
Volume 921.34(10) 
Z 2 
Density (calculated) 1.393 mg/m3 
Absorption coefficient, µ 0.875 mm-1 
F(000) 408 
Theta range for data collection 5.21-60.57 
Independent reflections 2327 
Completeness to theta 0.972 
Extinction coefficient 0.875 
Max. and min. transmission 1.000 and 0.607  
Absorption correction MULTI-SCAN method
Goodness-of-fit on F2 (S) 1.092
R indices (all data) R(reflections)=0.0251(2222)  
wR2(reflections)=0.0628(2327)
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Table 6. Selected bond lengths (Å) and angles (°), (Fig. 16). 
Bond lengths  (Å)  Bond angles (°) 
O3-C3 1.3761 (0.0022)  C9–O1–C9' 110.93 (0.13)
O3–C10 1.4223 (0.0022)  C8–C7–C1 111.26 (0.12)
O4–C4 1.3826 (0.0021)  C8'–C7'–C1' 111.31 (0.13)
O4–C10 1.4211 (0.0026)  C8'–C7'–O5 106.24 (0.12) 
O4'1-C4' 1.3738 (0.0021)  C1'–C7'–O5 112.31 (0.14)
O4'1-C4'1 1.4254 (0.0023)  C8'–C8–C9 103.35 (0.15)
O3'-C3' 1.3744 (0.0018)  C7–C8–C9 109.03 (0.12)
O3'-C3'1 1.4334 (0.0024)  C7–C8–C8' 112.90 (0.13)
O5–C7' 1.4274 (0.0019)  C9'–C8'–C8 102.93 (0.14)
O1–C9 1.3401 (0.0029)  C7'–C8'–C8 112.38 (0.14)
O2–C9 1.2139 (0.0023)  C7'–C8'–C9' 112.36 (0.14)
C7'–C8' 1.5402 (0.0022)  O3–C10–O4 109.13 (0.15)
C8–C9 1.5150 (0.0023)    
C8–C8' 1.5267 (0.0027)    
C8'–C9' 1.5365 (0.0025)    
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Appendix 
Appendix 1. Aryl substituents present in the synthetic procedures (Chapter 3, 4, and 5). 
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Appendix 2. 1H NMR data of lignanolactones (selected molecules). Only signals of lignan framework (2-8; 2'-9') are reported. 
Table 7. 1H NMR data of (7'S,8R,8'R)-7'-hydroxylignano-9,9'-lactones. 
 O
Ar' O
H
H
Ar
OH
 
(7'S)-27I,94 
(7'S)-7'-
hydroxyarctigenin 
(7'S)-15I,94
(7'S)-7'-
hydroxymatairesinol
(7'S)-124II,197
(7'S)-7'-
hydroxybursehernin
(7'S)-125fII 
(7'S)-7'-
hydroxyprestegane B 
(7'S)-25I 
(7'S)-parabenzlactone 
(7'S)-793 
(7'S)-7'-
hydroxyenterolactone
 Ar=Ar9, Ar'=Ar7 Ar=Ar'=Ar7 Ar=Ar9, Ar'=Ar5 Ar=Ar'=Ar8 Ar=Ar'=Ar5 Ar=Ar'=Ar2 
[α]24D -23.9° (c 0.56, CHCl3) -9.3° (c 4.0, THF) -20.09° (c 0.34, CHCl3) -1.5° (c 0.12, CHCl3) -1.5° (c 0.12, CHCl3) -1.32° (c 0.31, Acetone) 
MHz, 
Solvent  
500 MHz, 
CDCl3 
500 MHz, 
CDCl3 
500 MHz, 
CDCl3 
500 MHz, 
CDCl3 
500 MHz, 
CDCl3 
300 MHz, 
acetone-d6 
300 MHz, 
acetone-d6 
Position δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) 
δ; multipl.; J 
(Hz) δ; multipl.; J (Hz) 
7a 2.90-2.96; m 2.89-2.95; m 2.92-2.97; m 2.89-2.95; m 2.94-3.00; m 2.76-2.90, m 2.71; dd; 13.7, 5.0 
7b 3.00-3.08; m 3.01; dd; 15.3, 7.7 2.92-2.97; m 3.01; dd; 15.5, 8.0 2.94-3.00; m  2.76-2.90, m 3.02; dd; 13.7, 4.7 
8 2.90-2.96; m 2.89-2.95; m 2.89; dd; 13.0, 5.5 2.89-2.95; m 2.90; dd; 12.0, 6.0 2.76-2.90, m 2.99; m 
7' 4.66; dd; 6.0, 1.5 4.63; d; 6.6 4.64; dd; 6.5, 1.5 4.57; dd; 6.7, 2.3 4.61; dd; 6.2, 2.8 4.75; m 4.75; d; 5.7 
8' 2.59-2.67; m 2.56-2.63; m 2.56-2.62; m 2.60-2.66; m 2.54-2.60; m 2.62; m 2.68; m 
9'a 3.91; app. t; 8.8 3.88-3.98; m 3.95; app. t; 8.8 3.85-3.88; m 3.91; m 4.05; dd; 9.0, 7.8 3.88; t; 8.1 
9'b 3.99; dd; 9.5, 7.0 3.88-3.98; m 3.99; dd; 9.0, 6.5 3.89-3.92; m 3.91; m 4.09; dd; 9.0, 6.9 4.02; dd; 8.1, 7.8 
Aromatic 
protons 
6.61; dd; 8.0, 2.0 
6.65; d; 2.0 
6.73; d; 2.0 
6.75; dd; 8.5, 2.0 
6.79; d; 8.0 
6.81; d; 8.0 
6.60; dd; 7.9, 1.9 
6.61; s 
6.67; d; 1.8 
6.71; dd; 8.1, 1.8 
6.78; d; 7.8 
6.86; d; 8.0 
6.54-6.56; m, 2H 
6.65-6.69, m, 2H 
6.78; dd; 8.5, 1.5 
6.81; d; 8.5 
6.66; dd; 8.5, 2.0 
6.72; d; 2.0 
6.73-6.75; m, 2H 
6.79; d; 2.0 
6.80; d; 8.5 
6.58; dd; 8.0, 
1.5 
6.61; d; 1.0 
6.67; dd; 8.0, 
1.0 
6.68; d; 8.0 
6.70; d; 1.5 
6.74; d; 8.0 
6.55-6.58; m 
6.66-6.69; m, 
2H 
6.75-6.80; m, 
3H 
6.57; dt; 7.3, 1.2 
6.67; ddd; 7.8, 1.9, 1.0 
6.69; t; 1.2 
6.76; ddd; 8.1, 2.4, 1.0 
6.82; dt; 7.6, 1.2 
6.91; dd; 2.0, 1.9 
7.06; t; 8.6 
7.17; t; 7.8 
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Table 8. 1H NMR data of (7'R,8R,8'R)-7'-hydroxylignano-9,9'-lactones. 
 O
Ar' O
H
H
Ar
OH
 (7'R)-27
I,21,94 
(7'R)-7'-hydroxyarctigenin 
(7'R)-15I,21,94 
(7'R)-7'-hydroxymatairesinol 
(7'R)-793,169 
(7'R)-7'-hydroxyenterolactone 
(7'R)-144169 
(7'R)-7'-hydroxyenterolactone
dimethyl ether 
 Ar=Ar9, Ar'=Ar7 Ar=Ar'=Ar7 Ar=Ar'=Ar2 Ar=Ar'=Ar3 
[α]24D +8.8° (c 1.4, EtOH) -9.8° (c 4.0, THF) -13.04° (c 1.5, Acetone) –13.98° (c 3.0, CHCl3) 
MHz, 
Solvent  
500 MHz, 
CDCl3 
400 MHz, 
CDCl3 
300 MHz, 
Acetone-d6 
200 MHz, 
CDCl3 
Position δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) 
7a 2.65; ddd; 6.5, 6.5, 6.5 2.77; dd; 13.8, 5.2 2.76; dd; 13.7, 5.5 2.92-2.78; m 
7b 2.76; s 2.70; dd; 13.8, 7.9 2.85; dd; 13.7, 6.5 2.92-2.78; m 
8 2.75; s 2.64-2.59; m 2.95; ddd; 8.7, 6.5, 5.5 2.92-2.78; m 
7' 4.41; d; 6.8 4.38; d; 7.8 4.51; d; 4.8 4.39; d; 5.8 
8' 2.53; dddd; 7.8, 6.8, 6.7, 6.5 2.54-2.47; m 2.64; qd; 8.7, 4.8 2.59-2.52; m 
9'a 4.13; dd; 9.3, 7.8 4.16; dd; 9.5, 7.6 3.90; t; 8.7 4.0; dd; 9.2, 8.0 
9'b 4.39; dd; 9.3, 6.7 4.42; dd; 9.5, 5.6 4.21; t; 8.7 4.32; dd; 9.4, 7.4 
Aromatic 
protons 
6.78; d; 8.3, 2H 
6.70; d; 8.3 
6.67; dd; 8.3, 1.5 
6.63; m 
6.52-6.47; m, 2H 
6.43; d; 1.9 
6.48; dd; 8.0, 1.9 
6.55; d; 1.9 
6.62; dd; 8.1, 1.9 
6.76; d; 7.9 
6.82; d; 8.0 
6.67; dm; 7.8 
6.70; dm; 7.8 
6.73; dm; 7.8 
6.76; dm; 7.8 
6.77; m 
6.86; t; 2.0 
7.11; t; 7.8 
7.15; t; 7.8 
7.27-7.14; m, 2H 
6.84-6.63; m, 6H  
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Table 9. 1H NMR data of 7',8'-trans-8,8'-trans-lignano-9,7'-lactones, (7'S,8S,8'R). 
 O
H
Ar' O
RO
H
H Ar
 113a88,197,II,III 113b197,II 113cII 132I 127II 133a197 133b197 133c197 
 Ar=Ar'=Ar
5 
R=H 
Ar=Ar9, Ar'=Ar5 
R=H 
Ar=Ar'=Ar7 
R=H 
Ar=Ar'=Ar7 
R=TBDMS 
Ar=Ar'=Ar5 
NO2O2N
O
R=
 
Ar=Ar9, Ar'=Ar5 
R=MOM 
Ar=Ar5, Ar'=Ar9 
R=MOM 
Ar=Ar9, Ar'=Ar10 
R=MOM 
[α]24D +90.14° (c 0.4 CHCl3) +47.45° (c 1.08 THF) 
+52.68° (c 0.2, 
THF) 
+36.83° (c 0.57, 
THF) 
+66.81° (c 0.31, 
THF) (±) (±) (±) 
MHz, 
solvent 
500 MHz, 
CDCl3 
500 MHz, 
CDCl3 
500 MHz, 
CDCl3 
500 MHz, 
CDCl3 
500 MHz, 
CDCl3 
n.g., CDCl3 n.g., CDCl3 n.g., CDCl3 
Position δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) 
7a 3.15; dd; 14.0, 5.0 2.91-3.21; m 3.14-3.05; m 3.05; d; 5.5 3.22; dd; 14.0, 4.0 2.96-3.21; m 2.94-3.20; m 3.00-3.22; m 
7b 2.95; dd; 14.0, 7.0 2.91-3.21; m 3.14-3.05; m 3.05; d; 5.5 3.00; dd; 14.0, 7.5  2.96-3.21; m 2.94-3.20; m 3.00-3.22; m 
8 3.06; ddd; 12.0, 7.0, 5.0 2.91-3.21; m 3.14-3.05; m 3.15-3.10; m 2.91-2.87; m 2.96-3.21; m 2.94-3.20; m 3.00-3.22; m 
7' 5.13; d; 8.5 5.16; d; 9.2 5.11; d; 9.5 5.11; d; 9.0 5.04; d; 9.0 5.15; d; 9.2 5.12; d; 9.1 5.13; d; 10.7 
8' 2.28-2.22, m 2.18-2.39; m 2.32-2.27; m 2.26- 2.21; m 2.82-2.76; m 2.12-2.40; m 2.19-2.37; m 2.20-2.38; m 
9'a 3.55; dd; 3.5, 11.0 3.40-3.65; m 3.58; dd; 3.5, 11.0 3.49; dd; 3.5, 10.5 4.23; d; 6.0 3.44; dd; 10.3, 3.7 
3.42; dd; 10.6, 
2.8 
3.44; dd; 10.3, 
3.6 
9'b 3.48; dd; 4.0, 11.0 3.40-3.65; m 3.50; dd; 4.0, 11.0 3.41; dd; 3.5, 10.5 4.23; d; 6.0 3.30; dd; 10.3, 3.8 
3.27; dd; 10.3, 
3.9 
3.28; dd; 10.3, 
3.8 
Aromatic 
protons 
6.60; d; 1.5 
6.66; dd; 8.0, 1.5 
6.69; dd; 7.5, 1.5 
6.72; d; 1.5 
6.73; d; 7.5 
6.75; d; 8.0 
6.56-6.88; m, 6H 6.49; d; 2.0 
6.69; dd; 8.0, 1.5 
6.70; dd; 8.0, 2.0 
6.81; d; 1.5 
6.83; d; 8.0 
6.84; d; 8.0 
6.46; d; 2.0 
6.66; dd; 8.0, 2.0 
6.67; dd; 8.0, 2.0 
6.79; d; 2.0 
6.81; d; 8.0 
6.84; d; 8.0 
6.59; d; 1.5 
6.63; d; 7.5 
6.68; dd; 7.5, 1.5 
6.71; dd; 7.5, 1.5 
6.74; d; 1.5 
6.75; d; 7.5 
6.58-6.86; m, 6H 6.46-6.84; m, 6H 6.50-6.87; m, 6H 
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Table 10. 1H NMR data of 7',8'-trans-8,8'-cis-lignano-9,7'-lactones, (7'S,8R,8'R). 
 O
H
Ar' O
HO
H
H Ar
 126aII 126bII 126fI 110194 
 Ar=Ar'=Ar5 Ar=Ar9, Ar'=Ar5 Ar=Ar'=Ar11 Ar=Ar'=Ar7 
[α]24D +49.3° (c 0.3, THF) +44.47° (c 0.54, THF) +37.5° (c 0.3, CHCl3) +51.0° (c 0.005, THF) 
MHz, solvent 500 MHz, CDCl3 500 MHz, CDCl3 500 MHz, CDCl3 500 MHz, CDCl3 
Position δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) 
7a 3.22; dd; 15.0, 5.0 3.20; dd; 15.0,5.0 3.23; dd; 15.1, 4.5 3.16; dd; 15.0, 5.0 
7b 2.73; dd; 15.0, 10.5  2.74; dd; 15.0, 11.0 2.75; dd; 15.1, 10.6 2.76; dd; 15.0, 10.2 
8 3.04; ddd; 10.5, 8.0, 4.5 3.04; ddd; 11.0, 8.5, 5.0 3.09; ddd; 10.6, 8.2, 4.5 3.05; ddd; 10.2, 8.1, 5.0 
7' 5.49; d; 2.0 5.53; d; 2.0 5.45; d; 2.6 5.46; d; 2.6 
8' 2.56; ddd; 7.0, 4.5, 2.0 2.62-2.58; m 2.59-2.63; m 2.6; dddd; 8.1, 6.9, 4.4, 2.6 
9'a 3.95; dt; 10.5, 4.0 3.96; dd; 11.0, 4.5 3.93; dd; 10.5, 4.0 3.94; dd; 10.7, 4.4 
9'b 3.77; ddd; 10.5, 7.0, 5.5 3.78; dd; 11.0, 7.5 3.73-3.78; m 3.76; dd; 10.7, 6.9 
Aromatic 
protons 
6.66; dd; 8.0, 1.5 
6.69; d; 1.5 
6.72; d; 8.0 
6.75; dd; 8.0, 1.5 
6.76; d; 1.5 
6.80; d; 8.0 
6.65; dd; 8.0,1.5 
6.69; d; 1.5 
6.71; d; 8.0 
6.78; d; 2.0 
6.82; dd; 8.0, 2.0 
6.85; d; 8.0 
6.65; dd; 8.0, 2.0 
6.71-6.73; m, 2H 
6.74-6.77; m, 2H 
6.82; d; 8.1 
6.67; dd; 8.1, 2.1 
6.72; d; 2.1 
6.75; ddd; 8.1, 2.0, 0.8 
6.77; d; 2 
6.80; d; 8.1 
6.88; d; 8.1 
 
 
Table 11. 1H NMR data of 7',8'-cis-8,8'-trans-lignano-9,7'-lactones, (7'R,8S,8'R) and (7'S,8R,8'S). 
 O
Ar
Ar' O
RO
H
H H
O
H
Ar' O
RO
H
H Ar
 
 (−)-115185 (−)-114185 (+)-11531 (+)-11438 
 Ar=Ar'=Ar
5 
R=H 
Ar=Ar'=Ar5 
R=Piv 
Ar=Ar'=Ar10 
R=H 
Ar=Ar'=Ar10 
R=Piv 
[α]24D -42.1° (c 1.07, CHCl3) -46.8° (c 1.52, CHCl3) +20.0° (c 1.6, CHCl3) +30.0° (c 0.6, CHCl3) 
MHz, solvent 400 MHz, CDCl3 400 MHz, CDCl3 400 MHz, CDCl3 400 MHz, CDCl3 
Position δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) 
7a 3.08; dd; 14.2, 5.3 3.07; dd; 14.2, 5.1 3.08; dd; 14.0, 5.5 3.08; dd; 14.2, 6.8 
7b 2.99; dd; 14.2, 6.8 3.00; dd; 14.2, 7.3 3.02; dd; 14.0, 5.5 3.02; dd; 14.2, 4.9 
8 2.90; m 2.87; m 2.94; m 2.87; m 
7' 5.38; d; 7.8 5.38; d; 7.3 5.32; d; 7.7 5.32; d; 6.8 
8' 2.67; m 2.79; m 2.64; m 2.79; m 
9'a 3.31; m 3.60; dd; 11.7, 6.4 3.27; m 3.77; dd; 11.5, 5.9 
9'b 3.21; m 3.62; dd; 11.7, 6.4 3.16; m 3.62; dd; 11.5, 6.4 
Aromatic 
protons 
6.69-6.80; m, 6H 6.66-6.72; m, 4H 
6.75-6.78; m, 2H 
6.76-6.87; m, 4H 
6.67-6.72; m, 2H 
6.66; d; 8.3 
6.72-6.75; m, 2H 
6.82-6.85; m, 3H 
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Table 12. 1H NMR data of 7',8'-cis-8,8'-cis-lignano-9,7'-lactones, (7'R,8R,8'R). 
 O
Ar
Ar' O
RO
H
H H
 108b194 (±)-134211 
 Ar=Ar'=Ar
7 
R=H 
Ar=Ar'=Ar5 
R=TBDMS 
[α]24D +59.8 (c 0.005, THF) (±) 
MHz, solvent 500 MHz, CDCl3 400 MHz, CDCl3 
Position δ; multipl.; J (Hz) δ; multipl.; J (Hz) 
7a 3.08; d; 5.8 2.84; dd; 15.5, 10.5  
7b 3.08; d; 5.8 3.35; dd; 15.5, 3.4 
8 3.12; ddd; 10.2, 5.8, 5.8 3.10; m 
7' 5.12; d; 9.3 5.43; d; 5.4 
8' 2.30; dddd; 10.2, 9.3, 4.0, 4.1 2.52; m 
9'a 3.50; ddd; 11.0, 4.1, 3.9 3.28; d; 10.8 
9'b 3.57; ddd; 11.0, 4.0, 3.9 3.57; dd; 10.8, 2.6 
Aromatic 
protons 
6.49; d; 2.0 
6.69; dd; 8.0, 2.0 
6.70; ddd; 8.1, 2.0, 0.4 
6.81; d; 2 
6.82; d; 8.1 
6.83; d; 8.1 
6.71-6.79; m, 5H 
6.93; s 
 
 
Table 13. 1H NMR data of 7',8'-trans-8,8'-cis-8-alkyl-lignano-9,7'-lactones, (7'S*,8R*,8'R*). 
 O
Ar
Ar' O
RO
R'
H H
 128aII 128b197 128c197 
 
Ar=Ar'=Ar5 
R=H 
R'=Me 
Ar=Ar'=Ar5 
R=MOM 
R'=Me 
Ar=Ar'=Ar5 
R=MOM 
R'=Et 
[α]24D (±) (±) (±) 
MHz, solvent 500 MHz, CDCl3 CDCl3 CDCl3 
Position δ; multipl.; J (Hz) δ; multipl.; J (Hz) δ; multipl.; J (Hz) 
7a 2.99; d; 13.5 3.29; d; 13.6 3.38; d; 13.6 
7b 2.85; d; 13.5 2.71; d; 13.6 2.62; d; 13.5 
8 – – – 
7' 4.84; d; 10.5 4.83; d; 10.2 4.81; d; 10.5 
8' 2.44; ddd; 10.5, 8.0, 5.5 2.51-2.71; m 2.63-2.79; m 
9'a 4.01; dd; 11.5, 8.0 3.61-3.76; m 3.74; dd; 10.9, 9.6 
9'b 3.84; dd; 11.5, 5.5 3.44; dd; 9.8, 4.6 3.43; dd; 9.8, 4.6 
R' 1.37; s 1.41; s 1.16; t; 7.5  1.69-2.03, m 
Aromatic 
protons 
6.67; dd; 1.5, 8.0 
6.71; d; 1.5 
6.75; m, 2H 
6.78; d; 8.0 
6.81; d; 1.5 
6.26; d; 2.0 
6.62; dd; 8.1, 1.9 
6.72; s 
6.74; s, 2H 
6.78; s 
6.21; d, 1.9 
6.60; dd; 8.1, 2.0 
6.72; d; 8.5 
6.75; br s, 2H 
6.81; br s 
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Appendix 3.  
Table 14. Summary of the outcomes of the basic treatments of hydroxylignanolactones. 
Starting material Reagents Product(s) Outcome 
O
Ar' O
H
H
Ar
OH
 
 
(7'S)-25 
Ar=Ar'=Ar5 
2% KOH/MeOH 
Starting material 
O
H
Ar' O
HO
H
H Ar
 
 
113a 
Ar=Ar'=Ar5 
translactonization and  
α-epimerization 
NaH/DMF 
1M aq. NaOH/EtOH 
Starting material no reaction 2% KOH/t-BuOH 
2% aq. KOH/MeOH 
O
Ar' O
H
H
Ar
OH
 
 
(7'S)-112b 
Ar=Ar'=Ar11 
NaH/DMF 
O
H
Ar' O
HO
H
H Ar
 
 
113c 
Ar=Ar'=Ar7 
O
H
Ar' O
TBDMSO
H
H Ar
 
132 
Ar=Ar'=Ar7 
translactonization,  
α-epimerization,  
aromatic silyl cleavage and 
silyl migration 
O
Ar' O
H
H
Ar
OH
 
 
(7'S)-124 
Ar=Ar5, Ar'=Ar9 
2% KOH/MeOH 
Starting material 
O
H
Ar' O
HO
H
H Ar
 
 
113f 
Ar=Ar5, Ar'=Ar9 
translactonization and  
α-epimerization 
NaH/DMF 
O
H
Ar' O
HO
H
H Ar
 
 
113a 
Ar=Ar'=Ar5 
2% KOH/MeOH Starting material 
O
Ar' O
H
H
Ar
OH
 
 
(7'S)-25 
Ar=Ar'=Ar5
translactonization and 
 α-epimerization 
1M aq. NaOH/EtOH 
Starting material no reaction 2% KOH/t-BuOH 
2% aq. KOH/MeOH 
O
Ar' O
Me
H
Ar
OH
 
 
128a 
Ar=Ar'=Ar5 
2% KOH/MeOH 
Starting material 
O
Ar
Ar' O
HO
Me
H H
 
 
131a 
Ar=Ar'=Ar5 
translactonization NaH/DMF 
1M aq. NaOH/EtOH 
 
Errata 
 
 
Page 17. In the last paragraph the complete name of the lignan in Fig. 6 should be (8β,8'α)-
lignano-9,9'-lactone, and not (8α,8'β).  
Page 18. Fig. 6 should be as below. 
 
O
Ar Ar
O
H Hαβ  
 
 
We apologize for these oversights. 
 
